1 Gut microbiome shifts in adolescents after sleeve gastrectomy with increased oral-associated

2 taxa and pro-inflammatory potential

- 3 Cynthia O Akagbosu¹*, Kathryn E McCauley²*, Sivaranjani Namasivayam³*, Hector N Romero-
- 4 Soto³, Wade O'Brien⁴, Mickayla Bacorn³, Eric Bohrnsen⁵, Benjamin Schwarz⁵, Shreni Mistry⁶,
- 5 Andrew S Burns⁶, P. Juliana Perez-Chaparro⁶, Qing Chen³, Phoebe LaPoint³, Anal Patel³, Lauren
- 6 E Krausfeldt², Poorani Subramanian², Brian A Sellers⁷, Foo Cheung⁷, Richard Apps⁷, Iyadh
- 7 Douagi⁷, Shira Levy³, Evan P Nadler⁸**, Suchitra K Hourigan³**
- 8 * These authors contributed equally

9 ** These authors contributed equally

- Department of Gastroenterology. Weill Cornell Medicine. New York, New York,
 United States.
- Bioinformatics and Computational Biosciences Branch National Institute of Allergy
 and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United
 States.
- 15 3. Clinical Microbiome Unit. National Institute of Allergy and Infectious Diseases,

16 National Institutes of Health, Bethesda, Maryland, United States.

- 17 4. Dartmouth Geisel School of Medicine, Dartmouth College, Hanover, New
- 18 Hampshire, United States.
- 19 5. Research Technologies Branch, National Institute of Allergy and Infectious Diseases,
- 20 Division of Intramural Research, Rocky Mountain Laboratories, National Institutes of
- 21 Health, Hamilton, Montana, United States.

22	6.	NIAID Microbiome Program, National Institute of Allergy and Infectious Diseases,
23		National Institutes of Health, Bethesda, Maryland, United States.
24	7.	NIH Center for Human Immunology, Autoimmunity, and Inflammation (CHI),
25		Bethesda, Maryland, United States.
26	8.	Evan P Nadler. ProCare Consultants, Washington DC, Washington DC, United States.
27	Correspo	nding Author: Suchitra K Hourigan. Clinical Microbiome Unit. National Institute of
28	Allergy an	nd Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United
29	States. suc	chitra.hourigan@nih.gov
30	Word Co	unt: 3999
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		

42 ABSTRACT

Background: Bariatric surgery is highly effective in achieving weight loss in children and
adolescents with severe obesity, however the underlying mechanisms are incompletely understood,
and gut microbiome changes are unknown.

46 Objectives: 1) To comprehensively examine gut microbiome and metabolome changes after 47 laparoscopic vertical sleeve gastrectomy (VSG) in adolescents and 2) to assess whether the 48 microbiome/metabolome changes observed with VSG influence phenotype using germ-free 49 murine models.

50 Design: 1) A longitudinal observational study in adolescents undergoing VSG with serial stool 51 samples undergoing shotgun metagenomic microbiome sequencing and metabolomics (polar 52 metabolites, bile acids and short chain fatty acids) and 2) a human-to-mouse fecal transplant study.

Results: We show adolescents exhibit significant gut microbiome and metabolome shifts several 53 months after VSG, with increased alpha diversity and notably with enrichment of oral-associated 54 taxa. To assess causality of the microbiome/metabolome changes in phenotype, pre-VSG and post-55 VSG stool was transplanted into germ-free mice. Post-VSG stool was not associated with any 56 57 beneficial outcomes such as adiposity reduction compared pre-VSG stool. However, post-VSG stool exhibited an inflammatory phenotype with increased intestinal Th17 and decreased 58 regulatory T cells. Concomitantly, we found elevated fecal calprotectin and an enrichment of 59 proinflammatory pathways in a subset of adolescents post-VSG. 60

61 Conclusion: We show that in some adolescents, microbiome changes post-VSG may have 62 inflammatory potential, which may be of importance considering the increased incidence of 63 inflammatory bowel disease post-VSG.

3

64	What is already known on this topic: Bariatric surgery is highly effective in achieving weight				
65	loss in children and adolescents with severe obesity, however the underlying mechanisms are				
66	incompletely understood, and gut microbiome changes are unknown.				
67	What this study adds – Significant gut microbiome and metabolome shifts were found several				
68	months after vertical sleeve gastrectomy in adolescents, notably with enrichment of oral-associated				
69	taxa. Using human to germ-free mice fecal transplant studies, the post-surgery changes in the gut				
70	microbiome/metabolome were shown to have inflammatory potential. Furthermore, raised fecal				
71	calprotectin and inflammatory systemic pathways were seen in a subset of adolescents post-				
72	surgery.				
73	How this study might affect research, practice or policy – These findings may be of importance				
74	given the growing recognition of an increased incidence of inflammatory bowel disease after				
75	bariatric surgery and warrants further investigation.				
76					
77					
78					
79					
80					
81	Key words: bariatric surgery, microbiota, metabolome; children, adolescents, pediatric,				
82	inflammation, obesity, sleeve gastrectomy, childhood obesity, type 2 diabetes mellitus,				
83	dyslipidemia				

84

85 INTRODUCTION

The epidemic of childhood obesity continues unabated, with 19.3% of children and adolescents having obesity and 6.1% having severe obesity in the USA¹. Multiple comorbidities are associated with childhood obesity including type 2 diabetes mellitus (T2DM), metabolic dysfunctionassociated steatotic liver disease (MASLD), dyslipidemia, and continuation of obesity into adulthood^{2 3}. If weight loss can be achieved prior to entering adulthood, the risk of these conditions is mitigated. Therefore, childhood obesity is a key target for intervention⁴.

Bariatric surgery achieves significant weight loss and reduces or resolves associated comorbidities
in children with severe obesity⁵. Clinical guidelines recommend bariatric surgery as a potential
intervention for children and adolescents with class II obesity and comorbidities or class III obesity
with or without comorbidities^{6 7}. Laparoscopic vertical sleeve gastrectomy (VSG), with removal
of 80-90% of the greater curvature of the stomach, is the most common pediatric bariatric
procedure and the only type performed on those <13 years of age⁸.

Although VSG in children and adolescents is highly effective, the biological mechanisms underlying the weight loss and metabolic improvement are not fully elucidated. Restriction of food intake by reduction of stomach capacity plays an important role but the degree of enhanced metabolism post-VSG cannot be explained by caloric restriction alone. VSG also leads to weight loss through altered neurohormonal feedback mechanisms including increases in glucagon-like peptide-1 (GLP-1) and peptide YY, which reduces appetite⁹.

There has been growing interest in the role of the gut microbiome in the mechanisms behind VSG.
 Many studies have shown a difference in the gut microbiome between individuals with and without
 obesity ¹⁰. Moreover, murine models with fecal transplant (FT) from humans with obesity to germ-

107 free mice have shown transfer of the obesity phenotype indicating a causal role for the gut 108 microbiome¹¹. Studies examining gut microbiome changes after bariatric surgery in adults suggest 109 an increase in microbiota diversity and decrease in Firmicutes/Bacteroidetes ratio, although 110 specific changes differ between surgery type and amongst studies^{12 13}.

To our knowledge, the role of the gut microbiome in adolescents undergoing bariatric surgery has 111 not yet been examined¹⁴. This is uniquely important to study as the microbiome of children and 112 adolescents differs from adults¹⁵⁻¹⁷. The developing microbiome in childhood also plays a clear 113 role in establishing metabolic and inflammatory pathways that could impact energy regulation in 114 obesity¹⁸¹⁹. Additionally, there is mounting evidence suggesting that the age of onset of obesity 115 significantly impacts overall cardiometabolic risk, with childhood obesity possibly representing a 116 more virulent form of the disease as both MASLD and T2DM progress more rapidly in children 117 than adults²⁰⁻²². Thus, studying microbiome changes in children and adolescents may be of 118 particular importance. Furthermore, many of the studies in adults undergoing bariatric surgery 119 focused on Roux-en-Y gastric bypass, not VSG, used 16S rRNA gene microbiome sequencing, 120 and did not examine microbiome function and metabolites. Also, there are limited studies 121 examining whether the microbiota changes found with bariatric surgery have a causal role in the 122 123 beneficial phenotype changes seen post-surgery.

Therefore, we aimed to 1) deeply examine gut microbiome structure and function changes with VSG in adolescents using shotgun metagenomic sequencing and wide metabolomic analysis and 2) assess if the microbiome/metabolome differences seen have a causal role in the phenotypic changes observed with VSG by performing FT of stool from adolescents pre-VSG and post-VSG into germ-free mice.

129

130 **RESULTS**

131 Participants and clinical data

- 132 Twelve participants provided paired stool samples within the 8 weeks (mean 2 weeks) prior to
- 133 VSG (pre-VSG) and follow-up stool samples 3-7 months (mean 5 months) after VSG (post-VSG).
- 134 The mean age at VSG was 15 years (range 10-18 years), 8/12 participants were female and 9/12
- 135 Black or African American (Table 1). Notably, 2 participants were identical twins.
- 136 At VSG, subjects had a mean body mass index (BMI) of 48.7kg/m² which decreased to 39.9 kg/m²
- 137 (p<0.0001) post-VSG (Table 1). Total body weight loss (TBWL) averaged 17.8% (range 5.9% -
- 138 32.9%). 8/12 participants had T2DM or prediabetes pre-VSG with a reduction to 0/12 post-VSG
- 139 (p=0.0078). 7/12 participants had elevated alanine aminotransferase (ALT) pre-VSG, indicating a
- 140 high likelihood of MASLD; only 1/12 participants had a liver biopsy which showed metabolic
- 141 dysfunction-associated steatohepatitis. Overall, mean ALT decreased from 28.2 U/L to 15.7U/L
- 142 (p=0.0025) with VSG. 4/12 participants had dyslipidemia with elevated low-density lipoprotein
- 143 (LDL) pre-VSG compared to 1/12 post-VSG, with an increase in high-density lipoprotein (HDL)
- 144 cholesterol post-VSG from an average of 41.3 mg/dL to 49.0 mg/dL (p=0.0317).
- 145 Stool microbiome changes with VSG

i. Alpha and beta diversity

Pre-VSG and post-VSG stool samples underwent shotgun metagenomic sequencing. Bacterial diversity increased post-VSG (Shannon p=0.047, Inv Simpson p=0.04, Evenness (p=0.042) Fig.1A). Significant changes in microbiome composition (beta diversity) were seen using the Canberra distance, which places more weight on lower abundance species (p=0.015, Fig.1B) but not Bray Curtis distance. Pre-VSG, alpha diversity was significantly lower in those with diabetes

152 compared with pre-diabetes and no diabetes (SuppFig.1A) and microbiome composition also 153 differed (SuppFig.1B). Post-VSG, there were no differences in alpha or beta diversity between 154 those who previously had diabetes and the other subjects. There were no significant differences 155 between changes in alpha and beta diversity and other clinical parameters.

156 ii. Taxonomic shifts

There was a significant enrichment of 76 bacterial taxa post-VSG. Notably, the top 18 species enriched post-VSG were from the *Streptococcus* and *Actinomyces* genera (Fig.1C-1D. Supp Table 1). This included an enrichment of *Streptococcus salivarius, Streptococcus vestibularis, Streptococcus parasanguinis, Actinomyces oris* and *Actinomyces oral taxon*, all of which are commonly associated with the oral cavity. No individual taxa significantly correlated with clinical characteristics.

163 iii. Carbohydrate-Active Enzymes (CAZymes)

164 CAZymes were examined due to their role in influencing host metabolism²³. While the overall 165 composition of CAZymes only showed a moderate change with VSG (Canberra PERMANOVA 166 R2 = 0.049, P=0.056, Fig.2A), five specific CAZymes exhibited significant enrichment post-VSG 167 (Fig.2B, Supp Table 2). Many of the CAZyme enrichments post-VSG were associated with 168 *Streptococcus species* (Fig.2C). In addition, Glycoside Hydrolase 13 (GH13)+Carbohydrate 169 Binding Module 20 (CBM 20) significantly associated with increased TBWL (q=0.002, Supp 170 Table 2).

171 iv. Antibiotic resistance genes (ARGs)

ARGs were examined using the RGI CARD database. Four ARGs were enriched post-VSG: qacJ,
tetA(46), tetB(46) and vanY in vanF cluster (Fig.2D). These resistance genes, especially

tetAB(46), were primarily found in contigs belonging to several *Streptococcus* species enriched
post-VSG (Fig.2E).

176 v. Conserved functional enrichments

There were no functional pathway level differences with VSG. Therefore, reads were aligned to 177 Enzyme Commission (EC) gene annotations to identify more refined gene function differences. 178 There was a moderate change in lower-abundance genes post-VSG (Canberra R2=0.05, P=0.059, 179 SuppFig.2A), most notably with enrichment of EC 1.1.1.105, an all-trans retinol dehydrogenase 180 gene, from the oxidoreductases class (SuppFig.2B, Supp Table 3). In addition, these enriched ECs 181 formed three distinct modules of co-associated genes (blue, brown and turquoise) that increased 182 significantly post-VSG (SuppFig.2C-D), driven by different bacterial genera (SuppFig.2E). ECs 183 184 in the blue module were primarily from mevalonate, hemiterpene biosynthesis and heme biosynthesis pathways; those in the brown module focused on sugar acid degradation, and the 185 turquoise module contained several tRNA synthetases (Supp Table 3). 186

187 vi. Bacteriophage and viral composition

When looking at the DNA virome, there were no significant differences observed with VSG in taxonomy, host taxonomy, taxonomic diversity, taxonomic composition, viral protein family diversity or composition (SuppFig.3A-F). As most DNA viruses in the gut microbiome are phages, this suggests phage-containing bacteria did not significantly change with VSG despite large overall bacterial changes.

193 Stool metabolome changes with VSG

Post-VSG stool displayed higher ratios of secondary to primary bile acids compared to pre-VSG
stool (Fig.3A). Notably, this pattern was broad and included all ratios for which the corresponding
precursor primary bile acid and product secondary bile acid were detected.

Amongst polar metabolites, only the elevation of citrulline post-VSG passed a false discovery rate cut-off of 10% (Fig.3B). However, several trends known to be important to gut health were observed (Fig.3C). These included a decrease in acyl-carnitines, an increase in neurotransmitters known to be directly microbially produced (GABA, dopamine, and histamine), and increases in redox cofactor metabolites. No changes in SCFAs were observed.

Polar metabolites were related to a range of demographic and clinical factors (SuppFig.4, Supp 202 Table 4). Several amino acid metabolites (purple) positively associated with HDL, and negatively 203 204 associated with hemoglobin A1C (HbA1c) pre-VSG. In addition, several metabolites correlated negatively with BMI pre-VSG, including those in Redox and Co-Enzyme metabolite (CoA, FMN, 205 NADH), Glycolysis (G1P, Glycerol-3P), and Nucleotide (UMP, AMP) classes. Post-VSG, several 206 metabolites associated with the degree of TBWL, including neurotransmitters such as GABA and 207 Dopamine, which also correlated negatively with triglyceride levels. Citrulline did not correlate 208 with any factors pre-VSG or post-VSG. 209

210 Stool microbiome and metabolite correlations with VSG

To reduce the dimensionality of the microbiota, taxa were agglomerated into seven co-associated networks. Each increased in abundance post-VSG except for the red network, which exhibited a trending decrease (p=0.087; SuppFig.5A-B, Supp Table 5). Changes in these networks were correlated with changes in polar metabolites which revealed that the *Bacteroides* and the *Alistipes/Akkermansia/Actinomyces* prominent group both increased in concert with several

SCFAs including butyrate, isovalerate, and isobutyrate (SuppFig.5C, Supp Table 5). Conversely,
the *Streptococcus* prominent group had the fewest correlations, only exhibiting positive
correlations with isocitrate and cytidine and a negative correlation with urate.

219 FT into germ-free mice

Next, to assess whether the microbiome/metabolome changes seen with VSG had a phenotypic 220 221 effect, germ-free mice were inoculated with pre-VSG or post-VSG stool from the same participant (Fig.4A). Two human participants were chosen who had both pre-VSG and post-VSG stool stored 222 223 adequately in glycerol to preserve bacteria viability. Of note, one subject had the second-to-greatest TBWL and the second had prediabetes pre-VSG which resolved post-VSG. Using 16S rRNA gene 224 sequencing, 6 weeks post-FT, mice transplanted with post-VSG stool had a higher alpha diversity 225 226 (Fig.4B) and different bacterial composition (PERMANOVA Bray Curtis R2 = 0.114, P=0.006, adjusted for human inoculum source, Fig.4C) compared to mice that received pre-VSG stool, 227 228 which was similar to the human stool microbiota findings. The mouse microbiome samples did also show significant separation based on the human subject used as the inoculum (PERMANOVA 229 Bray Curtis R2=0.495, P=0.001, adjusted for FT timepoint). 230

231 Phenotype changes in germ-free mice

Phenotypic differences resulting from FT with pre-VSG and post-VSG stools were compared. Six weeks post-FT, there was no difference in body weight, food consumption, intraperitoneal glucose tolerance tests, nor tissue weights (epididymal fat, subcutaneous fat and liver weights) between mice that received pre-VSG versus post-VSG stool (Fig.4D-G respectively). Consistently, micro-computed tomography revealed no differences in subcutaneous or intraabdominal adipose tissue volume between the two groups (Fig.4H). There was a significant increase in serum resistin in

mice that received post-VSG stool compared to pre-VSG stool (p=0.047), but no differences in
other metabolic hormones (GLP-1, insulin, leptin, gastric inhibitory polypeptide, Fig.4I).

240 Immune and inflammatory changes in germ-free mice

Immune changes in the murine models were assessed in the large intestine lamina propria and 241 mesenteric lymph nodes using flow cytometry (SuppFig.6A). Of note, mesenteric lymph node data 242 was only available from one set of mice pre- and post-VSG FT. In the large intestine, there was a 243 significant decrease in $\gamma\delta$ T cells, a non-significant increase in CD4⁺ T cells and decrease in CD8⁺ 244 T and NK cells in post-VSG mice (Supp.Fig6B). More importantly, there was a significant increase 245 in the number and proportion of Th17 cells, along with a significant decrease in GATA3⁺ 246 regulatory T cell (Treg) proportion in the large intestine and mesenteric lymph nodes of post-VSG 247 248 mice (Fig.5A, Supp.Fig6C) suggesting an inflammatory phenotype in the individuals studied. Th17 cytokines (IL-17A and IL-22) were also increased in the mesenteric lymph node post-VSG 249 (SuppFig.6D) but did not reach significance in the colon. Sparse Partial Least Squares analysis of 250 251 the most discriminatory immune and metabolic readouts and microbial taxa showed a distinct separation of pre- and post-VSG parameters indicating a direct or indirect association between the 252 microbiota and observed immune milieu. Notably, the increased Th17 phenotype observed in the 253 post-VSG mice clustered with increases in relative abundances of microbial taxa belonging to 254 Ruminococcaceae, Erysipelatoclostridiceae, and Monoglobus. Conversely, the increased Treg 255 populations in the pre-VSG mice were associated with increased levels of the taxa Parabacteroides 256 (SuppFig.6E). 257

258 Inflammatory changes in humans with VSG

Given the inflammatory phenotype post-VSG observed in the murine model, colonic inflammatory 259 changes were assessed in available human stool samples by fecal calprotectin (FC). 8/12 260 participants had stool frozen without preservatives to allow for FC assessment. 6/8 individuals had 261 an increase in FC to a clinically elevated level post-VSG (>120ug/g, Fig.5B). Of these 6 262 participants, the mean FC pre-VSG increased from 47ug/g to 497ug/g post-VSG (p=0.0016, 263 264 Fig.5B). 2/8 patients with an elevated FC level pre-VSG had a decrease post-VSG. There was no correlation between length of time from surgery and FC levels. Subjects with raised FC post-VSG 265 did not report typical clinical symptoms associated with high levels such as diarrhea. Additionally, 266 267 the microbiome of subjects with increased FC also exhibited increased post-VSG microbiota similarity compared to pre-VSG where samples were more distinct (p for interaction=0.016, 268 Supplementary Fig.7A-B). No individual taxa correlated with FC increases. 269

To assess systemic immunity/inflammation changes with VSG, urine samples were utilized due to 270 the unavailability of blood samples. Proteomic analysis was performed using the SomaScan V4.1 271 Assay, where a subset of 1856 proteins were identified with detectable signals in urine from the 272 overall 7000 analyte panel that has been optimized for peripheral blood (SuppFig.8). When these 273 274 1856 proteins were compared between paired pre-VSG and post-VSG urine samples for 6 subjects, 275 no individual proteins differed significantly. However, 17 pathways exhibited significant positive enrichment post-VSG (FDR<0.05, Fig.5C). The top enriched pathways included 4 pathways 276 277 involved in immune/inflammation regulation: IRAK2 mediated activation of TAK1 complex; 278 TICAM1, TRAF6-dependent induction of TAK1 complex; IRAK1 recruits IKK complex; and IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation. Enrichment in all 4 pathways was 279 driven by the same set of 3 leading edge proteins related to ubiquitin, and the increased expression 280 observed post-VSG was conserved across participants with one exception (Fig.5C). 281

282 **DISCUSSION**

We comprehensively examined stool microbiome and metabolome changes pre- and post-VSG in 283 284 adolescents and assessed if these changes were causal in VSG-associated phenotypes using a 285 murine FT model. Our major findings were 1) increased microbiome diversity post-VSG, with enrichment of several taxa, most notably in those usually associated with the oral cavity; 2) 286 287 increased ratios of secondary to primary bile acids post-VSG; 3) no differences in metabolic phenotypes in germ-free mice transplanted with pre-VSG and post-VSG stool; 4) an inflammatory 288 phenotype in germ-free mice transplanted with post-VSG stool compared to pre-VSG stool defined 289 290 by an increase in $\gamma\delta$ T cells and Th17 cells and decrease in GATA3⁺ Tregs in the gut and a systemic increase in resistin and 5) a corresponding inflammatory phenotype in a subset of adolescents post-291 292 VSG with an increase in FC.

In our cohort, the gut microbiome increased in diversity and changed in composition with VSG. 293 Generally, an increase in alpha diversity is seen with all forms of bariatric surgery in adults, but 294 specific compositional and taxa changes vary by surgery type and study^{13 24}. In our study, there 295 was enrichment of taxa post-VSG, most notably in species commonly found in the oral cavity from 296 the Streptococcus and Actinomyces genera. Some other studies examining microbiome changes 297 post-VSG in adults have also seen an increase in these genera, although species could not be 298 accurately identified due to the use of 16S rRNA sequencing²⁵. This increase in oral-associated 299 taxa post-VSG is likely through a variety of mechanisms, including removing some of the physical 300 barrier with VSG that usually prevents the passage of oral taxa and also an increase in stomach pH 301 post-VSG²⁶. These changes are very likely due to VSG itself as they are rarely described in weight 302 loss alone²⁷. These changes may have potential microbial and immunological consequences. 303 Specifically, post-VSG within the enriched *Streptococcus* species, there was CAZyme enrichment 304

of GH13+CBM 20, a combination shown in fungi to enhance complex starch degradation²⁸. Moreover, several ARGs enriched post-VSG were within the enriched *Streptococcus* species. These findings collectively suggest that the *Streptococcus* species that become enriched in the gut microbiome post-VSG are augmented for functions that may enhance their virulence. Overall, the increase in oral-associated taxa may be clinically relevant as there has been increasing recognition that enrichment of oral taxa in the gut maybe associated with several adverse inflammatory patient outcomes, including inflammatory bowel disease (IBD) and subclinical coronary atherosclerosis²⁹⁻

312 ³¹.

313 There were significant changes in the stool metabolome and microbiome function post-VSG, many of which are considered beneficial. There was a broad increase in the microbiota-driven conversion 314 of host-derived primary bile acids into secondary bile acids post-VSG, suggesting bolstering of 315 the host-to-microbiome communication cycle post-VSG³². Further, citrulline, which is understood 316 as both a marker of gut health and to have a role in obesity, was increased post-VSG ^{33 34}. This 317 molecule participates in the regulation of numerous pathways relevant to obesity and a therapeutic 318 effect of citrulline supplementation in the regulation of obesity associated metabolic imbalances 319 has also been suggested³⁵⁻³⁸ Moreover, microbially metabolized neurotransmitters including 320 GABA, dopamine, and histamine also trended upward post-VSG in support of a gut-neural 321 homeostasis improvement³⁹. Lastly, there was post-VSG enrichment of EC 1.1.1.105, an all-trans 322 retinol dehydrogenase gene, with Vitamin A signaling and homeostasis reported to play a role in 323 mitigating obesity⁴⁰. Overall, it is difficult to assess whether these potentially beneficial trends in 324 fecal metabolites are a result of VSG, post-VSG weight loss or both. The absence of SCFAs 325 changes post-VSG was notable, as changes have previously been reported in an adult study⁴¹. 326 Large inter-sample variance may have obscured trends in our cohort. 327

An assessment for a causal role of the microbiome/metabolome changes with VSG performed via 328 FT into germ-free mice did not identify favorable phenotypes such as decreased adiposity or 329 improved glucose tolerance in mice that received post-VSG stool. These findings contrast with 330 similar studies performing human to mouse FTs reporting improvements in body fat, glycemic 331 control and energy expenditure⁴²⁻⁴⁴ However, those studies involved stool samples from older 332 adults who were prediabetic or diabetic and employed mouse models that differed in age and sex 333 of mice, fecal inoculation, experimental timelines, and diet administered. We may not have seen 334 similar changes as the mice were harvested at 6 weeks following FT, which may not have been 335 long enough to allow phenotypic changes to develop, and only one of the human participants used 336 for FT had prediabetes pre-VSG. 337

An intriguing finding in our mouse model was the inflammatory phenotype in those receiving post-338 VSG stools. Given that obesity is considered an inflammatory condition and subjects used for FT 339 experienced weight loss, decreased inflammation in mice receiving post-VSG FT was expected⁴⁵. 340 Indeed, a decrease in different measures of inflammation has been seen following both weight loss 341 of patients with obesity and in one report of decreased gut and systemic inflammation in adults 342 post-VSG^{46 47}. Conversely, we observed an increase in the systemic levels of resistin in post-VSG 343 mice, an adipokine increasingly being recognized as playing a role in inflammation^{48 49}. Moreover, 344 Th17 cells were increased and GATA3+ Tregs were decreased in the large intestine and mesenteric 345 lymph nodes of post-VSG mice. Numerous studies have described the role of Th17 and imbalance 346 of Th17/Treg ratio in inflammatory bowel disease^{50 51}. With relevance to VSG, one study of adults 347 undergoing VSG reported decreases in peripheral Tregs⁴⁷. Further, Erysipelatoclostridiceae that 348 positively correlated with Th17 in our study has been previously associated with inflammation in 349 mouse models^{52 53} In contrast, a recent study in mice demonstrated the beneficial role of 350

microbiota-induced Th17 in protection against diet-induced obesity and metabolic syndrome, a finding not observed in our model⁵⁴. Collectively these data indicate that stool microbiome/metabolome changes from VSG in humans may have gut and systemic inflammatory potential when transplanted to germ-mice, although the underlying mechanisms remain to be elucidated.

356 When inflammation was assessed in our pediatric participants, FC, a gut specific marker of inflammation, was found to be raised in a subset of adolescents post-VSG, to levels well above the 357 normal reference range. Two studies in adults report persistently raised FC levels after bariatric 358 surgery, with one study showing a persistent increase above baseline 1-year post-VSG.^{55 56}. 359 Interestingly in all studies including ours, raised FC levels did not correlate with adverse 360 gastrointestinal symptoms or TBWL. In our study, systemically, 4 pathways involved in 361 immune/inflammation regulation were enriched post-VSG, driven by proteins related to ubiquitin. 362 Ubiquitination of the IKK complex mediated via proteins IRAK and TRAF-6 is an important step 363 in the activation of the NF-kB pathway that plays a critical role in the immune response to microbes 364 including the transcription of pro-inflammatory genes such as IL-2, IL-6, IL-12, TNFa, activation 365 of macrophages and differentiation of CD4⁺ T cells⁵⁷. Increased activation of this pathway has 366 been demonstrated as an important driver of IBD⁵⁸. Furthermore, the gut microbiota has been 367 shown to modulate the expression of this signaling cascade and thus directly influence gut 368 inflammation⁵⁹⁻⁶¹. 369

Elevated FC levels and enrichment of pathways related to pro-inflammatory responses in humans post-VSG and an increased proportion of intestinal Th17 in comparison to Tregs, with increased resistin levels in mice colonized with post-VSG microbiota, collectively suggest an inflammatory state of subjects post-VSG. This may be clinically relevant given studies, including a large case

series and two national database studies, showing an increased incidence of IBD after bariatric 374 surgery⁶²⁻⁶⁴. One study reported an increased incidence of ulcerative colitis, but not Crohn's 375 disease, with VSG⁶³. It is widely accepted that IBD is at least in part a gut microbiome-mediated 376 disease in susceptible individuals⁶⁵. Therefore, we postulate that the large shifts in the gut 377 microbiome seen post-VSG can have inflammatory potential, and in certain individuals, this may 378 379 increase their risk of IBD or other inflammatory diseases. It could be argued that increases in FC may be related to the actual VSG rather than gut microbiome changes resulting from VSG. 380 381 However, against this, is the inflammatory phenotype seen in mice transplanted with post-VSG stool who did not receive surgery themselves and the level of FC post-VSG not correlating with 382 the length of time post-surgery. 383

Our findings by no means negate the many beneficial effects of VSG in adolescents with obesity. However, they do highlight a new finding that microbiome changes post-VSG may be inflammatory in some adolescents. This paves the way for further research to gain insight into potential inflammatory mechanisms with gut microbiota changes post-VSG. Additionally, larger studies of children and adolescents undergoing VSG followed for a longer period are needed to assess whether microbiome changes and inflammation are persistent, and if those with persistent inflammatory changes are at increased risk for adverse outcomes such as IBD.

Despite this being the first study to our knowledge to comprehensively examine microbiome and metabolome changes post-VSG in adolescents and show that these changes with VSG can be potentially inflammatory, the study has many limitations. The sample size is limited, partly due to the limited number of adolescents undergoing VSG. Additionally, longitudinal samples after 7 months post-VSG were unavailable. While a large increase in oral-associated taxa was seen in the stool post-VSG, no oral samples were available to confirm whether the same taxa from the oral

397 cavity were engrafting in the gut within a specific participant. Additionally, if these oral taxa 398 contribute to the inflammatory phenotype remains to be determined. Finally, a complete 399 assessment of inflammation in adolescents was limited as only stool and urine were available and 400 limited samples were available for the FT murine models to assess whether the findings held across 401 the participant cohort.

402 In conclusion, large changes in the stool microbiome and metabolome were seen in adolescents post-VSG. There was a notable enrichment of oral-associated taxa in the gut post-VSG. The post-403 VSG changes in the gut microbiome/metabolome were shown to have inflammatory potential 404 when transferred to a germ-free mouse model. Furthermore, raised FC and inflammatory systemic 405 pathways were seen in a subset of adolescents post-VSG. While VSG is highly effective for weight 406 407 loss and reduction of comorbidities in adolescents with obesity, we show the novel finding of potential inflammatory microbiome changes post-VSG. This may be of importance given the 408 growing recognition of an increased incidence of IBD after bariatric surgery and warrants further 409 investigation. 410

- 411
- 412
- 413
- 414
- 415
- 416
- 417

418 METHODS

419 EXPERIMENTAL MODEL AND SUBJECT DETAILS

420 HUMAN METHODS AND ANALYSIS

421 Subjects and samples

Children and adolescents undergoing VSG between January 2021 to February 2023 were enrolled 422 in an Institutional Review Board (IRB) approved longitudinal cohort study "Biorepository of 423 Specimens for Pediatric Obesity Research Use" (Children's National Hospital IRB protocol 424 #Pro00015976) with signed consent and assent (latter for those >11 years). Inclusion criteria were 425 children and adolescents (≤ 21 years) undergoing vertical sleeve gastrectomy at the Children's 426 National Hospital in Washington DC. To be eligible for surgery, children 19 and under required a 427 $BMI > 120^{th}$ percentile of 95th percentile for age and sex with an obesity-related comorbidity 428 and/or BMI $\geq 140^{\text{th}}$ percentile. 429

430 Participants were enrolled up to 2 months prior to their planned VSG. After consent was obtained, a stool and urine collection container were mailed to participants. For stool, participants mailed 431 back a sample aliquoted in an OMNIgene-gut tube and OMNImet-gut tube for DNA and 432 metabolite preservation respectively (DNA Genotek Inc)⁶⁶. Wherever possible participants also 433 returned whole stool aliquoted into tubes with glycerol (for bacterial preservation) and whole stool 434 without preservatives. Participants gave a clean catch urine sample mixed with AssayAssure ® 435 Genelock (Sierra Molecular) for protein preservation. All samples were mailed back overnight on 436 icepacks and stored at -80°C until analysis. The same procedure was followed for post-VSG 437 samples. Clinical data was obtained via extraction of medical records from clinical appointments 438 pre-VSG and post-VSG and patient collected data accompanying the samples and was stored in a 439

secure REDCap database. For clinical data analysis, BMI, weight, HbA1c%, LDL, HDL,
triglycerides, and ALT passed Shapiro-Wilks normality and were compared pre-VSG and postVSG via paired t-tests. T2DM, dyslipidemia, and hypertension were compared via McNemar exact
tests.

444 Patient involvement

Patients were involved in the design and conduct of the trial. We received input from patients in prior trials for the design of convenient sample collection methods that would minimize inconvenience and were suitable for the planned downstream assays. We intend to disseminate the main results to study participants.

449 Microbiome sequencing

DNA Extraction: DNA was extracted from human and murine fecal samples in two stages. First, 450 approximately 50 mg of fecal material and 650 µL MBL lysis buffer from the PowerMicrobiome 451 DNA/RNA EP Kit (Qiagen) were added to Lysis Matrix E (LME) tubes (MP Biomedicals). LME 452 tubes were transferred to a Precelleys 24 Tissue Homogenizer (Bertin Technologies) and fecal 453 454 samples were homogenized, centrifuged, with the resultant supernatant transferred to a deep-well 96-well plate. The second stage consisted of DNA isolation from the above supernatant using the 455 MagAttract PowerMicrobiome DNA/RNA EP Kit (Qiagen) on an automated liquid handling 456 457 system as detailed by the manufacturer (Eppendorf).

458 Shotgun Metagenomic Sequencing: Total gene content of the microbiome was assessed through 459 shotgun metagenomic sequencing. Metagenomic libraries were constructed from 100 ng of DNA 460 as starting material using the Illumina DNA Prep kit. Illumina DNA/RNA UD Indexes were used 461 to add sample-specific sequencing indices to both ends of the libraries. An Agilent 4200

TapeStation system with High Sensitivity D5000 ScreenTape (Agilent Technologies, Inc) was used to verify quality and assess final library size. A positive control (MSA-2002 20 Strain Even Mix Whole Cell Material (ATCC)) and a buffer extraction negative control were included. Metagenomic libraries were normalized and pooled at an equimolar concentration. Final pools were diluted to 750 pM and sequenced on a NextSeq2000 sequencer using a paired-end (100x100) NextSeq 1000/2000 P2 (200 cycles) kit (Illumina, Inc).

468 Microbiome analysis

Data Processing: The quality of raw paired-end sequence reads was assessed with FastOC⁶⁷ and 469 MutiQC⁶⁸. Adapters revealed by FastQC were removed using bbtools' bbduk software. Reads then 470 underwent the Whole Genome Sequence Assembly 2 (WGSA2)⁶⁹ protocol using the Nephele 471 platform⁷⁰ (version 2.24.2). In brief, reads were processed with fastp⁷¹ and minimal trimming and 472 filtering by ensuring an average read quality of 10, a trim of the 3' end of the read at a quality of 473 15 and trimming of the 5' end at a Q score of 20, with additional filtering of reads if they were less 474 than 60 bases after trimming. Decontamination was undertaken using Kraken2⁷² with a database 475 containing the human and mouse genome. After adapter trimming and filtering, samples contained 476 between 15M and 30M paired-end reads, of which between 8.7M and 22M were classified to the 477 bacterial kingdom. Taxonomic identification was performed on the trimmed, error-corrected, and 478 decontaminated reads in Kraken2 with the default RefSeq database. 479

Assembly and Gene Annotation: Within the WGSA2 pipeline, the trimmed, error-corrected and decontaminated reads were assembled into contiguous sequences, or contigs, using metaSPAdes⁷³.
Reads were recruited back to contigs using bowtie29 and SAMtools⁷⁴ to produce information on scaffold coverage and quality. Protein coding regions (CDS) were predicted from assembled scaffolds using prodigal. Predicted CDS regions were processed by EggNog-mapper2⁷⁵ to identify

and annotate genes with KEGG Orthology (KO), Enzyme Commission (EC) and Clusters of
Orthologous Genes (COG) identifiers. Abundances were calculated using verse⁷⁶ to obtain
Transcripts Per Million (TPM) at the CDS level and summed to obtain TPM by gene.

488 CAZymes: Carbohydrate Active Enzymes (CAZymes) were annotated from assembled metagenomic scaffolds using the dbCAN software⁷⁷ in meta mode with default settings and default 489 490 databases to obtain eCAMI, HMMER and DIAMOND-based annotations. Annotations were provided at the gene level and merged with predicted gene abundances. Genes were also annotated 491 492 with taxonomy using Kraken2, creating a table of CAZyme abundances both stratified by taxonomy and unstratified. Gene abundances were normalized to copies per million before 493 494 analysis. The eCAMI-based CAZyme identification was used in analysis and focused specifically on CAZymes supported by DIAMOND or HMMER when available. 495

Antibiotic Resistance Genes: Antibiotic resistance genes were identified using the Comprehensive
Antibiotic Resistance Database with the Resistance Gene Identifier tool v6.0.1, nudging loose hits
to strict and including low quality assemblies with prediction of partial genes (ref). Resulting
annotations were processed as for CAZymes.

Virome: After assembly with WGSA2, assembled scaffolds and binary alignment maps (BAM) 500 were processed for the presence of viral diversity (ssDNA, dsDNA phage, and giant DNA viruses) 501 using Nephele's DiscoVir pipeline (https://nephele.niaid.nih.gov/pipeline details/discovir/). 502 503 Briefly, geNomad predicted viral genomes and fragments using default confidence parameters as defined by the tool, and VERSE calculated read counts of viral genomes based on BAM files^{78 79}. 504 Next, CheckV assessed quality and all scaffolds identified as viral were retained for downstream 505 processing and analysis⁸⁰. Viral genomes and fragments greater than 1000 basepairs were clustered 506 with bbtools and MMseqs2 to generated vOTUs which were functionally annotated with DRAM-507

v with KOfam, Pfam, and Viral Orthologous Group (VOG) databases. Auxillary metabolic genes
 were identified with VirSorter2.0 and DRAM-v⁸¹⁻⁸³. Phage hosts were predicted using iPHoP⁸⁴.

510 Statistical Analysis: All statistical analysis of the microbiome was performed using R 4.3.0. For 511 taxonomic analysis, reads were filtered to those that aligned to the bacterial kingdom and normalized with rarefaction to 8 million reads per sample. Several measures of alpha diversity 512 513 were calculated, including Chao1 Richness, Observed Taxa, Evenness, Inverse Simpson, and Shannon Diversity using estimate richness from phyloseq⁸⁵. For all data types, Bray Curtis and 514 Canberra distance matrices were calculated using phyloseq's distance function. Alpha diversity 515 516 was compared between pre-VSG and post-VSG samples using linear mixed-effects models within the lmerTest package⁸⁶. The composition of the microbiome was compared against study 517 covariates with Permutational Analysis of Variance (PERMANOVA) using the adonis2 function 518 from the vegan package⁸⁷. Significant relationships were visualized using Principal Coordinates 519 Analysis (PCoA) ordination in phyloseq and ggplot2⁸⁸. All differential abundance analyses were 520 undertaken with Maaslin289, wherein data was analyzed with linear models after log-521 transformation. Features were filtered if they exhibited a minimum prevalence of less than 10% 522 and a minimum variance of 0.01. When paired samples were included, Subject ID was provided 523 524 as a random effect. An FDR-corrected p-value less than 0.2 was considered significant.

525 Co-associated networks of taxa or EC abundances were generated using Weighted Gene Co-526 Association Network Analysis⁹⁰. In brief, this tool reduces multi-dimensional data to co-associated 527 networks or modules. For taxa-based modules, taxa were included that were found to change 528 nominally after surgery at a false-discovery-corrected p-value of less than 0.5. Blockwise modules 529 were generated using a soft power threshold of 14, an unsigned topology overlap matrix, minimum 530 module size of 20, merge cut height of 0.15, and deepSplit of 3. This process generated eight

modules of taxa that were annotated manually by combining the taxonomic information, the average abundance of the taxon across samples, and the module membership, calculated as the correlation of the taxon abundance with the module eigengene.

WGCNA modules were also created for EC abundances using similar settings. ECs were included if they changed significantly due to surgery at an FDR P-value of 0.4. Modules were constructed using the same parameters as above except with a soft power threshold of 7. This resulted in four distinct modules of ECs. These were described using the pathway enrichment tool OmePath⁹¹, where scores used were based on module membership and calculated as described previously.

Relationships between module eigengenes and metabolites were identified using linear mixed
effects models. Results were visualized using the igraph package21 if they were significant at an
FDR p-value less than 0.05. Directionality of the results was represented by edge color and data
type was indicated through color of nodes.

543 This work utilized the computational resources of the NIH HPC Biowulf cluster 544 (http://hpc.nih.gov) and the NIAID Locus cluster (http://locus.niaid.nih.gov).

545 Metabolomics

546 *Metabolite and Lipid Sample Preparation:* For all liquid chromatography mass spectrometry 547 (LCMS) methods, LCMS-grade solvents were used. For bile acid analysis 400 μ L of homogenized 548 feces was taken from the fecal collection tubes and added to 500 μ L of ice-cold methanol. To each 549 sample 5 μ L of the Bile Acid SPLASH® (Avanti Polar Lipids Inc.) and 2 μ g of butylated 550 hydroxytoluene was added. Samples were agitated via shaking at 4°C for 20 minutes and then 551 centrifuged at 16k xg for 20 min. An aliquot of the supernatant was taken directly for liquid LCMS 552 analysis.

For short-chain fatty acid (SCFA) and polar metabolomics, a separate 400 μ L aliquot of homogenized feces was added to 400 μ L of water. Following mixing, 400 μ L of chloroform was added. Samples were shaken for 30 minutes at 4°C and subsequently centrifuged at 16k xg for 20 min. 400 μ L of the top (aqueous) layer was collected. The aqueous layer was sub-aliquoted for SCFA derivatization or diluted 5x in 50% methanol in water and prepared for LCMS injection.

558 SCFA Derivatization: To preserve SCFAs for analysis an aliquot of the aqueous fraction was derivatized with O-benzylhydroxylamine (O-BHA) as previously described with modifications⁹² 559 93 . The reaction buffer contained 1M pyridine and 0.5 M hydrochloric acid in water. To 35 μ L of 560 561 sample, 10 µL of 1M O-BHA in reaction buffer and 10 µL of 1M 1-Ethyl-3-(3dimethylaminopropyl) carbodiimide in reaction buffer were added. Samples were derivatized for 562 2 hours at room temperature with constant agitation. Addition of 50 µL of 0.1 % formic acid was 563 used to quench the reaction, which eliminated the potential for formate to be measured in these 564 samples. To extract derivatized molecules 400 µL of ethyl acetate was added. The samples were 565 centrifuged at 16k xg and 4°C for 5 min to induce layering. The upper (organic) layer was collected 566 and dried under vacuum. Samples were resuspended in 300 µL of water for LCMS injection. 567

Liquid Chromatography Mass Spectrometry: Tributylamine and all synthetic molecular references
were purchased from Millipore Sigma. LCMS grade water, methanol, isopropanol and acetic acid
were purchased through Fisher Scientific.

All samples were separated using a Sciex ExionLCTM AC system and measured using a Sciex 5500
 QTRAP® or Sciex 6500+ QTRAP® mass spectrometer.

Polar metabolites were analyzed as previously described⁹⁴. For all metabolomics analysis, quality
control samples, consisting of a mixture of the analyzed samples, were injected after every 10

injections to control for signal stability. Samples were analyzed via separate negative ionization 575 and positive ionization methods. For negative mode analysis, a Waters Atlantis T3 column (100 Å, 576 3 μ m, 3 mm \times 100 mm) with a gradient from 5 mM tributylamine, 5 mM acetic acid in 2% 577 isopropanol, 5% methanol, 93% water (v/v) to 100% isopropanol over 15 min was used. For 578 positive mode analysis, samples were separated on a Phenomenex Kinetex F5 column (100 Å, 2.6 579 580 μ m, 2.1 mm \times 100 mm) column with a gradient from 100% water with 0.1% formic acid to 95% acetonitrile with 0.1% formic acid over 5 min. Each metabolite was measured using at two distinct 581 multiple reaction monitoring (MRM) signals and a defined retention time. 582

583 For SCFA analysis samples were separated on a WatersTM Atlantis dC18 column (100Å, 3 μ m, 3

584

mm X 100 mm) with a 6 min gradient from 5-80 % B with buffer A as 0.1 % formic acid in water

and B as 0.1 % formic acid in methanol. All SCFA were measured using positive ionization using

586 MRMs that featured the characteristic 91 daughter ion from O-BHA derivatization. Identity was 587 confirmed via comparison to previous standards.

Bile acid samples were separated on a Phenomenex Kinetex® Polar C18 (100Å, 2.6 μm, 3 mm X
100 mm) using a binary gradient of A: 0.01 % acetic acid in water and B: 0.01 % acetic acid in
methanol. A 20 min gradient from 40-100 % B was utilized for separation. Samples were detected
in negative MRM mode using previously validated MRMs⁹⁵. Internal bile acid standard signals
were used to confirm signal identities and retention times.

Metabolomic analysis: All signals were integrated using SciexOS 3.1 (AB Sciex Pte. Ltd.). Signals with greater than 50% missing values were discarded and the remaining missing values were replaced with the lowest registered signal value. All signals with a QC coefficient of variance greater than 30% were discarded. Metabolites with multiple MRMs were quantified with the higher signal-to-noise MRM. Filtered datasets were total sum normalized prior to analysis. The

598 SCFA dataset and the two polar metabolomics datasets were scaled and combined using common 599 signal for serine and succinate for the positive mode metabolite method and the SCFA method 600 respectively. A paired t-test was used for all bile acid and metabolite statistics and a Benjamini-601 Hochberg method for correction for multiple comparisons was imposed where indicated.

602 Fecal Calprotectin (FC)

FC was assessed using the Buhlmann Fecal Calprotectin ELISA kit (BÜHLMANN fCAL®
ELISA, https://buhlmannlabs.com/buhlmann-fcal-elisa/) following the manufacturer's guidelines.
The FCs included all subjects who did not pass Shapiro-Wilks normality, so pre- and post-VSG
were compared via a Wilcoxon test. FCs excluding outliers passed normality and were compared
pre- and post-VSG via a paired t-test.

608 Urine Proteomics

Urine samples were analyzed using the SomaScan V4.1 Assay, an aptamer-based quantitative 609 proteomic biomarker discovery platform (SomaLogic; Boulder, CO). The assay was run according 610 to manufacturer specifications which includes pH adjustment and buffer exchange by gel filtration 611 prior to normalizing total protein concentration of urine samples to a standard input concentration 612 (https://somalogic.com/wp-content/uploads/2023/09/D0005009 Rev1 2023-09 SomaScan-7K-613 v4.1-UrinePre-processing-User-Manual.pdf). Data was then subjected to the manufacturer's 614 standard normalization methods, including adaptive normalization by maximum likelihood by 615 SomaLogic. 616

617 Identified enriched gene sets were determined utilizing the pre-ranked gene-set enrichment 618 analysis (GSEA) algorithm, as implemented in the FGSEA R package⁹⁶. Genes were prioritized 619 based on moderated T statistics derived from the limma model's relevant coefficient, and

enrichment analysis was conducted using the Reactome database, with correction of p values 620 applied for multiple sampling. This analysis can be used to identify significant enrichment of a set 621 of foreground genes or proteins, in predefined gene sets, compared against a reference set. Quality 622 control and initial data processing performed 623 were using an R package (https://github.com/foocheung/sqs) and Shiny app⁹⁷. 624

625 MOUSE METHODS AND ANALYSIS

626 Mice and FT

627 Germ-free C57BL/6NTac were bred and maintained at the NCI or NIAID Gnotobiotic animal facility. Mice were screened by microbiological culture and 16S rRNA PCR to ensure their germ-628 free status. Mice were fed a standard irradiated 5KAI diet (LabDiet). Pre-VSG and post-VSG 629 fecal samples from two human subjects stored in 20% glycerol at -80°C were used for fecal 630 microbiota transplant (FMT) into 5-6 week old male mice. Each mouse was orally inoculated with 631 200 µl of 35-60 mg stool slurry resuspended in sterile pre-reduced PBS in the anaerobic chamber. 632 Stool suspension was stored in a hungate tube. Each mouse was housed in a separate cage in 633 biocontainment racks in the same facility following inoculation. Body weights and feed 634 635 consumption was measured weekly and stool samples were collected for sequencing. Experiments were performed independently for each human subject and 4-6 mice were inoculated with either 636 pre-VSG or post-VSG stool samples for each subject. All procedures were performed in 637 638 accordance with approved animal study proposals by NCI or NIAID Animal Care and Use Committees. 639

640 Glucose tolerance test

Mice were fasted overnight for 12-14 hours. Glucose (2g/kg body weight) was administered intraperitoneally, and glucose measurements were performed via tail bleeds using a glucometer (DSS Precision Xtra) before and at 15, 30, 60, 90, and 120 mins after glucose administration.

644 Micro-computed tomography (Micro-CT)

QuantumGX scanner was used to obtain in-vivo high-resolution micro-CT imaging. Mice were anesthetized using 2.5% isoflurane, eyes protected with Artificial Tears ointment and transferred onto the imaging bed and maintained on 2% isoflurane during the imaging process. Images were obtained in 3 slices at 70 mm magnification and reconstructed. Adipose tissue for each mouse was quantified and analyzed using Analyze14 software. Intra-abdominal and subcutaneous fat were isolated using a threshold range of approximately -300 to -50 Hounsfield units.

651 Tissue harvest and isolation of cells from large intestine and mesenteric lymph nodes

Immediately after micro-CT imaging animals were euthanized with CO₂ and blood was collected 652 653 by cardiac exsanguination. Subcutaneous fat from the abdominal region, epididymal fat pads, and liver were harvested and weighed. Mesenteric lymph nodes were harvested and cells were isolated 654 655 by passing through a 70-µm cell strainer, centrifuged at 1500 rpm for 5 mins for flow cytometry 656 analysis. Large intestines (LI, cecum and colon) were collected and placed on ice-cold complete 657 media (RPMI 1640 supplemented with 20mM HEPES, 2mM L-glutamine, 1mM sodium pyruvate, 1mM nonessential amino acids, 50 mM β-mercaptoethanol, 100U/ml penicillin and 100 mg/ml 658 659 streptomycin) + 3% fetal bovine serum (FBS). The tissue was then opened longitudinally, fecal contents removed and cut into 1-2 cm pieces, and incubated in 20 ml of complete media + 3% FBS 660 + 5mM EDTA + 0.145 mg/ml DL-dithiothreitol for 20 mins at 37°C and 5% CO² with shaking. To 661 remove epithelial cells, LI were strained and vigorously shaken in a 50 ml tube containing 10 ml 662

663	complete media + 2mM EDTA, thrice. LI were then finely chopped and digested with 10 ml of
664	digestion media (complete media + 0.1 mg/ml Liberase TL, Roche + 0.05% DNase I, Sigma) for
665	25 mins at 37°C and 5% CO ² with shaking. The digestion was stopped by adding 10 ml complete
666	media + 3% FBS. Digested tissues were then passed through 100-µm cell strainers, centrifuged at
667	1500 rpm for 5 mins, followed by straining through 40- μ m cell strainers and centrifugation at 1500
668	rpm for 5 mins. Isolated lamina propria cells were then resuspended in complete media + 10%
669	FBS for flow cytometry analysis.

670 Spectral flow cytometry

Isolated single-cell suspensions were assessed for cytokine production potential by stimulation 671 672 with Cell Stimulation cocktail 500X (Thermo Fisher Scientific) prepared in complete media + 10% FBS for 2.5 hours at 37°C. To assess lymphoid cells, cells were incubated with Zombie NIR 673 Fixable Viability Dye for 15 mins at room temperature. Cells were then washed and incubated with 674 675 a cocktail of fluorescently labeled antibodies prepared in PBS + 1% FBS +10% Brilliant Stain Buffer + 10% TruStain FcX for 25 mins in the dark at 4°C: anti-CD45, anti-TCRβ, anti-CD44, 676 677 anti-CD90.2, anti-CD8_β, anti-CD4, anti-TCR $\gamma\delta$ and anti-NK1.1. Cells were then fixed/permeabilized in eBioscience FoxP3 Fixation/Permeabilization Solution kit overnight at 4°C 678 679 and stained with a cocktail of fluorescently labelled antibodies against intracellular antigens prepared in eBioscience intracellular staining buffer: anti-FoxP3, anti-GATA3, anti-RORyt, anti-680 Tbet, anti-IFNy, anti-IL17A and anti-IL22. 681

All samples were collected on an Aurora spectral cytometer (Cytek). Spectral unmixing was
 performed using single-control controls using cells from corresponding tissues or UltraComp
 eBeads (Invitrogen) and data were analyzed using FlowJo version 10.

685 Serum metabolic hormones measurement

Mouse serum concentrations of metabolic hormones were assessed using the Hormone Exp Panel kit (Millipore, MMHE-44K-06) according to the manufacturer's protocol and measured using Luminex MAGPIX Instrument (Bio-Rad). Data were analyzed using GraphPad Prism9.0 (Graph Pad software, La Jolla, CA, USA) with unpaired t-tests. Differences were considered to be statistically significant when p<0.05.

691 Microbiome sequencing:16S ribosomal RNA Gene Sequencing

692 DNA extraction was as per human samples. Microbiome composition was assessed via dual-index amplification of the V4 region of the 16S ribosomal RNA gene (16S rRNA). This method used the 693 V4 16S rRNA 515F and 806R primers with individual sample-specific indices and Illumina 694 sequencing adapters appended as previously described⁹⁸. The V4 region was amplified using: 5 695 µM of F/R primers, 1X Phusion High-Fidelity DNA Polymerase (New England Biolabs) and 100 696 ng of DNA as starting material. PCR conditions for amplification were as follows: initial template 697 denaturation at 98°C for 60s; 25 cycles of denaturation at 98°C for 10s, primer annealing 55°C for 698 30s, and template extension at 72°C 60s; with a final template extension at 72°C for 5 min. AMPure 699 XP beads (Beckman-Coulter) at a 1:1 ratio with the above PCR reaction were used to isolate final 700 PCR products. 701

Final 16S rRNA V4 libraries were quantified using the KAPA qPCR Library Quantification Kit (Kapa Biosystems) and pooled at an equimolar concentration. Pools were normalized to 8 pM, spiked-in with 15% phiX control library (Illumina) to add sequence diversity, and sequenced on the Illumina MiSeq instrument utilizing the 600 cycle Paired-End (250x250) Reagent Plate with the addition of 16S V4 rRNA specific sequencing primers⁹⁸.

707 Microbiome analysis

708 Samples collected from the murine study at six weeks as well as the human inoculum (pre-VSG 709 and post-VSG samples from two subjects) underwent 16S rRNA sequencing on the Illumina 710 MiSeq. The resulting sequences were reviewed for quality using FastQC and multiQC through Nephele's microbiome analysis platform. Sequences were trimmed to 210 bases on the forward 711 712 reads and 180 bases on the reverse read, and those with a maximum expected error greater than two were filtered out, reads then underwent Divisive Amplicon Denoising Algorithm 2 (DADA2) 713 utilizing Nephele's microbiome analysis platform⁹⁹. After the identification of sequence variants 714 715 through denoising, they were checked for chimeras and assigned taxonomy up to the species level using the SILVA database. If a sequence variant aligned to multiple species with 100% identity, all 716 717 species were listed. Once reads were agglomerated into a table of counts, reads from negative controls were subtracted from samples to be conservative about potential sources of contamination. 718

The sequence variant table was rarefied to 70,000 reads per sample after reviewing rarefaction curves and sequences available per sample. Alpha diversity metrics, including Chao1 richness, Evenness, Inverse Simpson and Shannon diversity values, as well as a Bray Curtis distance matrix, were calculated using phyloseq. Linear models determined differences in alpha diversity, and vegan's PERMANOVA utilizing marginal adjustment for the subject that served as the inoculum source identified differences in community composition between the gut microbiome of pre-VSG and post-VSG mice.

726 Multi-Omic analysis

DIABLO from the mixOmics package implemented sparse Partial Least Squares (sPLS) to
 perform discriminant analysis of multi-omic data¹⁰⁰. Extensive k-fold cross validation and leave-

729	one-out analysis was performed but did not provide stable estimates to obtain an optimal number
730	of features. Therefore, the top 10 most discriminant features from each data type and human
731	inoculum sources that differentiated pre-VSG mice from post-VSG mice were selected for
732	inclusion in the combined visualization of microbiota and flow data sources.
733	
734	
735	
736	
737	
738	
739	
740	
741	
742	
743	
744	
745	
746	
747	

748 FIGURE LEGENDS

Fig.1. Microbial taxa exhibit significant changes after VSG. (A) Subjects exhibited increases in several alpha diversity metrics post-VSG (LME P-value < 0.05). (B) Significant changes in underlying microbiota were also observed (Canberra PERMANOVA $R^2 = 0.06$, P=0.015). (C) Taxa enriched post-VSG included several members of the *Streptococcus* and *Actinomyces* genera (FDR P < 0.05). (D) All taxa at a species level that significantly increased post-VSG in order of coefficient. Abbreviations: VSG: vertical sleeve gastrectomy, FDR: False Discovery Rate, LME: Linear Mixed Effects; PERMANOVA: Permutational Analysis of Variance.

Fig.2. Carbohydrate-Active Enzymes (CAZymes) and Antibiotic Resistance Genes (ARGs) 756 identified from metagenomic data exhibit increases in Streptococcus species after VSG. (A) 757 Composition of CAZymes shows moderate change (Canberra PERMANOVA R2 = 0.049, 758 P=0.056). (B) Interrogating specific CAZymes, five exhibited significant enrichments post-VSG 759 (MaAsLin2, FDR P < 0.25). (C) Heatmap shows significant CAZyme genes from panel B, 760 761 stratified by gene-based taxonomy. (D) Antibiotic Resistance Genes enriched (Pfdr < 0.1) after surgery. (E) Antibiotic resistance genes with the largest effect size, tetA(46) and tetB(46) identified 762 primarily in Streptococcus contiguous sequences. Abbreviations: VSG: vertical sleeve 763 gastrectomy, CBM: Carbohydrate Binding Module, CPM: Copies Per Million, GH: Glycoside 764 Hydrolase, PERMANOVA: Permutational Analysis of Variance. 765

Fig.3. Stool metabolite changes with VSG. (A) Bile acid levels assessed by LC-MS/MS and the conversion ratios were calculated to reflect known primary to secondary bile acid, and unconjugated to conjugated bile acid substrate/product pairs. Ratios post- vs. pre-VSG were analyzed by a paired t-test and the fold change and significance of the change are reflected as the color of each node and the size of each node by row respectively in the displayed heatmap. All

771 measured ratios are displayed. (B) Polar fecal metabolites were assessed by LC-MS/MS and total sum normalized prior to analysis. Paired fold changes of post- vs pre-VSG and significance by 772 paired t-test are displayed with a false discovery rate of 10 % indicated at p=0.0012, calculated via 773 a Benjamini-Hochberg correction. Pathways and molecular families of interest are indicated via 774 color. (C) A heatmap of the paired post- vs. pre-VSG changes displayed in (B) broken out by 775 776 participant to display variance and observed pathway-driven trends in metabolite levels. All displayed features have a raw p<0.1 via a paired t-test. Abbreviations: LC-MS/MS: Liquid 777 Chromatography Mass Spectrometry, VSG: vertical sleeve gastrectomy, Acyl-Carn: acyl-778 779 carnitines, Neuro: neurotransmitters, Nucleic: nucleic acids, nucleosides, and nucleotides, Org. Acids: organic acids, SCFA: short-chain fatty acids 780

781 Fig.4. Fecal transplant with pre-VSG and post-VSG stool into germ-free mice. (A) Schematic of experimental design. Pre-VSG and post-VSG stool samples were inoculated (FT) into two 782 groups of germ-free mice (n=4-6/group). Body weights and feed consumption were measured 783 every week and mouse stool samples collected at 6 weeks were sequenced and analyzed. At week 784 6 following FT, a glucose tolerance test was performed. Following micro-CT imaging, mice were 785 sacrificed for sample collection. The experiment was repeated using samples from two 786 787 participants. (B) Alpha diversity was higher among mice receiving post-VSG stool, compared to those receiving pre-VSG stool. (C) Mice also exhibited compositional differences between pre-788 789 VSG and post-VSG stool, which was distinct from inoculum samples. (D)Weight change in mice 790 following FMT with pre-VSG and post-VSG stool is shown as a percentage of starting weight. No significant differences were found. (E) No differences in feed consumption between the two groups 791 were found. (F) Glucose tolerance tests showed blood glucose levels at different time points of the 792 test (left) and the area under the curve for the entire test is plotted (right) for the two groups. The 793

two participants are identified as shown in the key. (G) Weight measurements for epididymal and 794 subcutaneous fat pads and liver tissues are plotted for the two groups. (H) Micro-CT results 795 showing adipose areas examined in the mouse (top left), total adipose tissue volume (top right), 796 subcutaneous adipose tissue volume (bottom left), and intraabdominal adipose tissue volume 797 (bottom right). No differences were seen between groups. (I) Serum metabolic hormone 798 799 measurements. Resistin was higher following FT with post-VSG stool compared with pre-VSG stool; no other differences were seen. Abbreviations: VSG: vertical sleeve gastrectomy, FT: fecal 800 801 transplant.

Fig.5. Immune and inflammation assessment in mice and humans. (A) Representative contour 802 plots depicting RORyt+ and GATA3+ Treg populations and Th1 and Th17 populations from the 803 lamina propria cells of the large intestine (left). Gating strategy is shown in SuppFig.6A. The 804 number of live cells for each of the CD4+ T cell subsets and their proportion are plotted (right). 805 Data are based on FMT from 2 participants as shown in the key and are displayed as mean \pm 806 standard error of the mean. Statistical significance between the pre-VSG and post-VSG groups 807 was calculated using an unpaired Student's t-test and non-significance (ns) or p-values are 808 indicated. (B) Fecal calprotectin levels in all human subjects who had paired stool samples 809 810 available (n=8, top) and all subjects who had an increase in calprotectin with VSG (n=6, bottom). (C) Urine proteomic pathways significantly enriched post-VSG. 1856 proteins quantified in urine 811 812 were compared between timepoints before and after VSG for 6 subjects and ranked by t-statistic for enrichment analysis using Reactome gene sets. All pathways significantly positively enriched 813 for an increase in change post-VSG are shown (FDR adjusted p < 0.05), with enrichment score 814 and significance indicated by plotted color and size (left). For 4 pathways of interest, expression 815 observed for the 3 leading-edge proteins is shown for all subjects and timepoints measured, where 816

817 RFU indicates relative fluorescence units (right). Abbreviations: VSG: vertical sleeve818 gastrectomy.

SuppFig.1. Pre-VSG, microbiome diversity and composition related to Type 2 Diabetes status differed, but resolved post-VSG. (A) Subjects with established diabetes exhibited significantly distinct bacterial microbiota diversity (P < 0.05). (B) Microbiota composition was also highly distinct between subjects with established T2DM and those without (Bray Curtis PERMANOVA R²=0.44, P = 0.001). Abbreviations: VSG: vertical sleeve gastrectomy, T2DM: type 2 diabetes mellitus, PERMANOVA: Permutational Analysis of Variance.

SuppFig.2. Enzyme Commission genes found to be differentially abundant post-VSG formed 825 three distinct modules of co-associated genes. (A) PCoA Plot of Enzyme Commission 826 composition using Canberra distance. R^2 and p-values are derived from PERMANOVA. (B) 827 Differentially abundant enzyme class post-VSG. Enzyme class to the left decrease post-VSG and 828 enzymes to the right increase post-VSG. (C) Hierarchical clustering representation of WGCNA 829 830 modules based on moderately differential (FDR P < 0.4) pre- and post-VSG. Identified modules are represented by their color underneath the dendrogram. (D) All modules exhibited increases in 831 abundance post-VSG (LME P < 0.01). (E) Genera in the microbiome that contribute to each of the 832 three differentially abundant networks described in panels (C) and (D). Abbreviations: VSG: 833 vertical sleeve gastrectomy, FDR: False Discovery Rate, LME: Linear Mixed Effects, PCoA: 834 835 Principal Coordinates Analysis, PERMANOVA: Permutational Analysis of Variance, WGCNA: Weighted Gene Co-Association Network Analysis. 836

SuppFig.3. Metagenomic Viral Diversity and composition is not impacted by vertical sleeve
gastrectomy. (A) Identified viruses were primarily comprised of Caudoviricetes. Donut plot
represents abundances across both pre-VSG (left) and post-VSG (right) samples for each

taxonomic category. (B) Host taxonomy of identified viruses including Bacteroides, 840 Bacteroidaceae, and Prevotella, as well as several with no known hosts. As in (A), plot represents 841 summarized abundances across both pre-VSG (left) and post-VSG (right) samples for each viral 842 host. (C) Viral taxonomic diversity does not change due to VSG with respect to either Chaol 843 richness or evenness. (D) Viral taxonomic composition does not change significantly due to VSG. 844 845 Exploration of either (E) viral Protein Family (PFAM) diversity or (F) composition did not reveal significant differences due to VSG. Points indicate individual samples and lines connect paired 846 samples. P-values for diversity were generated from a linear mixed-effects model with the subject 847 as the random effect. Ellipses in composition plots represent 20% confidence intervals for each 848 group. PERMANOVA calculated the R^2 and p-values with the subject as the strata variable. 849 Abbreviations: VSG: vertical sleeve gastrectomy, PERMANOVA (Permutational Analysis of 850 Variance), PFAM (Protein Family). 851

SuppFig.4. Metabolites (circles) correlate with clinical variables (squares) (A) prior to and (B)
after VSG (p < 0.05). Pink lines indicate positive associations between metabolites and clinical
variables while blue lines indicate negative associations. Relationships were identified with nonparametric statistics (Wilcox Rank-sum for binary variables and Spearman correlation for
continuous variables). Abbreviations: VSG: vertical sleeve gastrectomy, AA: Amino Acid, FACar: Fatty Acid Carnitines, TCA: Tricarboxylic Acid, NT: Neurotransmitter, SCFA: Short Chain
Fatty Acid.

SuppFig.5. Metabolites change in concert with networks of taxa. (A) Taxa exhibiting at least
moderate change after VSG (P FDR < 0.5) formed several co-associated networks using Weighted
Gene Co-Association Network Analysis (WGCNA). (B) These networks were characterized by
specific taxa that collectively changed in abundance. P-values were generated from linear mixed

effects models. (C) These differential networks changed in concert with several changing 863 metabolites. Each line indicates a significant Spearman correlation between the change of 864 metabolites (difference in value before and after) and the change in microbial taxa (difference in 865 mean abundance before and after). Positive correlations are indicated in pink and negative 866 correlations are indicated in blue. The weight of the line indicates the strength of the correlation. 867 868 Modules identified in panels (A) and (B) are noted by their characteristic taxa. Abbreviations: VSG: vertical sleeve gastrectomy, AA: Amino Acid, FA-Car: Fatty Acid Carnitine, TCA: 869 Tricarboxylic Acid, NT: Neurotransmitter, SCFA: Short Chain Fatty Acid. 870

871 SuppFig.6. Additional flow cytometry data of mice receiving FT with pre-VSG and post-VSG

stool. (A) Gating strategy for lymphoid cells is shown. (B) Number of live lymphoid cells in the 872 873 large intestine lamina propria and mesenteric lymph node are plotted. (C-D). Number of live cells for each of the CD4⁺ T cell subsets, their proportion in the mesenteric lymph node (C) and 874 proportion of cytokine producing CD4⁺ T cells (D) are plotted. Groups and participants are 875 identified as shown in the key in (B). Data are displayed as mean \pm standard error of the mean. 876 Statistical significance between pre-VSG and post-VSG groups was calculated using unpaired 877 Student's t-test and non-significance (ns) or p-values are indicated. (E) Top 10 Amplicon sequence 878 879 variants and flow cytometry features that discriminate pre-VSG vs post-VSG samples from each subject used for FT (n=36 features) identified using mixOmics; rows are z-score scaled. 880 881 Abbreviations: FT: fecal transplant, VSG: vertical sleeve gastrectomy.

SuppFig.7. (A) PCoA plot representing the 6 subjects with increasing calprotectin values post-VSG, in which post-VSG samples become more related to each other. PERMANOVA calculated the interaction between before-vs-after VSG samples (time) and calprotectin. (B) Paired Distance within Pre-VSG samples, within Post-VSG samples, and between Pre-VSG and Post-VSG

886	samples, showing that distance within Pre-VSG samples exhibit higher distance than distances
887	within Post-VSG samples. P-values calculated with Wilcoxon Rank-Sum Test.

888 **SuppFig.8.** Validation of urine proteomics against serum proteomics in a separate pediatric cohort. 889 The SomaScan Assay utilizes 7000 SOMAmer Reagents optimized for detection of proteins in peripheral blood serum or plasma. To determine the subset that could be measured in urine, 890 891 SOMAmer Reagents were classified by comparing their average signal in a cohort of 53 urine samples to background and saturation thresholds. SOMAmer Reagents with a signal-to-noise ratio 892 893 <1.7 (n=5705) or a saturating signal of RFU >80000 (n=35) were excluded. 1856 SOMAmer 894 Reagents remained within the detectable range of the assay when using urine in this cohort of samples. 895

Supp Table 1. Excel file containing taxa enriched post-VSG, related to Figure 1.

897 Supp Table 2. Excel file containing CAZymes enriched post-VSG, post-VSG CAZymes related

to Total Body Weight Loss, Antibiotic Resistance Genes enriched post-VSG, related to Figure 2.

899 Supp Table 3. Excel file containing Enzyme Commission genes enriched post-VSG and

pathway enrichments of EC networks, related to Supplemental Figure 2.

Supp Table 4. Excel file containing pre-VSG and post-VSG correlations between metabolites
and clinical metadata, related to Supplemental Figure 4.

Supp Table 5. Excel file containing module assignments of bacterial taxa and correlations
between bacterial taxa module changes and metabolite changes, related to Supplemental Figure
5.

906

907

908 ACKNOWLEDGEMENTS

909 DATA AVAILIBILITY STATEMENT

- All data generated or analyzed during this study are included in this published article and its online
- 911 supplemental information files.
- 912 Sequencing reads for human and murine analyses are deposited in the Sequence Read Archive
- 913 (SRA) under accession number PRJNA1093424 at the following reviewer link:
- 914 https://dataview.ncbi.nlm.nih.gov/object/PRJNA1093424?reviewer=gbe14pmjol31cvc64bn6vh4f
- 915 <u>4r</u>.
- 916 Metabolite data is deposited at
- 917 https://figshare.com/articles/dataset/Supporting data for bariatric surgery patient fecal metab
- 918 olomics_and_bile_acid_measurements/25864327.
- 919 This paper does not report original code.
- 920

921 FUNDING

This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health under the Division of Intramural Research, NIAID, NIH (Hourigan), BCBB Support Services Contract HHSN316201300006W/75N93022F00001 to Medical Science & Computing (McCauley, Subramanian, McCauley), the Thrasher Research Fund Early Career Award #01484 (Akagbosu), and the American Pediatric Association Research in Academic Pediatrics Initiative on Diversity (RAPID) grant with funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grant R25DK096944

929 (Akagbosu). The funders had no role in the design and conduct of the study; collection, 930 management, analysis, and interpretation of the data; preparation, review, or approval of the 931 manuscript; and decision to submit the manuscript for publication. The content is solely the 932 responsibility of the authors and does not necessarily represent the official views of the National 933 Institutes of Health.

934 The authors acknowledge the NCI Gnotobiotic Animal Facility Staff for their assistance in

performing the germ-free mice experiments. This work used the Office of Cyber Infrastructure

and Computational Biology High Performance Computing cluster at NIAID, Bethesda, MD and

937 the Center for Genetic Medicine Research in the Children's National Research Institute under Dr.

938 Robert Freishtat.

939 AUTHOR CONTRIBUTIONS

940 Cynthia O Akagbosu, Kathryn McCauley and Sivaranjani Namasivayam contributed equally to941 this paper (first authors).

Evan P Nadler and Suchitra K Hourigan contributed equally to this paper (senior authors).

943 C.O.A., S.N., E.P.N. and S.K.H. conceived and designed the project. All authors acquired,

analyzed, or interpreted data from the study. K.E.M., S.N., H.N.R-S., M.B., B.S., Q.C. and F.C.

945 performed statistical analysis. C.O.A and S.K.H. obtained funding for the project. E.P.N and

946 S.K.H supervised the project. C.O.A., K.M., S.N., B.S. and S.K.H. wrote the original draft. All

947 authors reviewed and edited the manuscript, approved the final submitted manuscript and have

- agreed both to be personally accountable for the author's own contributions and to ensure that
- 949 questions related to the accuracy or integrity of any part of the work, even ones in which the

950	author was not	personally involved,	are appropriately	v investigated,	resolved,	and the re	esolution
-----	----------------	----------------------	-------------------	-----------------	-----------	------------	-----------

951 documented in the literature.

952 ETHICS DECLARATIONS

- 953 Ethics approval and consent to participate:
- 954 The study was approved by an Institutional Review Board (Children's National Hospital IRB
- protocol #Pro00015976) and all participants provided written informed consent \pm assent to
- 956 participate.

957 **Declaration of interests:**

- 958 B.A.S. is a former SomaLogic, Inc. (Boulder, CO, USA) employee and a company shareholder.
- All other authors declare that they have no competing interests.

960			
961			
962			
963			
964			
965			
966			
967			
968			

969 ABBREVIATIONS

- 970 VSG: Vertical Sleeve Gastrectomy
- 971 T2DM: Type 2 Diabetes Mellitus
- 972 MASLD: metabolic dysfunction-associated steatotic liver disease
- 973 FT: Fecal transplant
- 974 GLP-1: Glucagon-like peptide-1
- 975 BMI: Body mass index
- 976 TBWL: Total body weight loss
- 977 ALT: Alanine aminotransferase
- 978 LDL: Low-density lipoprotein
- 979 HDL: High-density lipoprotein
- 980 CAZymes: Carbohydrate-Active Enzymes
- 981 ARG: Antibiotic resistance genes
- 982 EC: Enzyme Commission
- 983
- 984 SCFA: Short-chain fatty acids
- 985 HbA1c: Hemoglobin A1C
- 986 FC: Fecal Calprotectin
- 987 IBD: Inflammatory Bowel Disease
- 988

- 990
- 991
- 992
- 993
- 994
- 995
- 996

REFERENCES

998	1. National Institute of Diabetes and Digestive and Kidney Diseases Overweight & Obesity
999	Statistics NIDDK 2021 [Available from: https://www.niddk.nih.gov/health-
1000	information/health-statistics/overweight-obesity accessed May 24 2024.
1001	2. Andes LJ, Cheng YJ, Rolka DB, et al. Prevalence of Prediabetes Among Adolescents and
1002	Young Adults in the United States, 2005-2016. JAMA Pediatr 2020;174(2):e194498. doi:
1003	10.1001/jamapediatrics.2019.4498 [published Online First: 20200203]
1004	3. Simmonds M, Llewellyn A, Owen CG, et al. Predicting adult obesity from childhood obesity:
1005	a systematic review and meta-analysis. Obes Rev 2016;17(2):95-107. doi:
1006	10.1111/obr.12334 [published Online First: 20151223]
1007	4. Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and
1008	cardiovascular risk factors. N Engl J Med 2011;365(20):1876-85. doi:
1009	10.1056/NEJMoa1010112
1010	5. Inge TH, Courcoulas AP, Jenkins TM, et al. Weight Loss and Health Status 3 Years after
1011	Bariatric Surgery in Adolescents. N Engl J Med 2016;374(2):113-23. doi:
1012	10.1056/NEJMoa1506699 [published Online First: 20151106]
1013	6. Pratt JSA, Browne A, Browne NT, et al. ASMBS pediatric metabolic and bariatric surgery
1014	guidelines, 2018. Surg Obes Relat Dis 2018;14(7):882-901. doi:
1015	10.1016/j.soard.2018.03.019 [published Online First: 20180323]
1016	7. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and
1017	Treatment of Children and Adolescents With Obesity. Pediatrics 2023;151(2) doi:
1018	10.1542/peds.2022-060640
1019	8. Steinberger AE, Nickel KB, Keller M, et al. National Trends in Pediatric Metabolic and
1020	Bariatric Surgery: 2010-2017. Pediatrics 2022;150(6) doi: 10.1542/peds.2022-057316
1021	9. McCarty TR, Jirapinyo P, Thompson CC. Effect of Sleeve Gastrectomy on Ghrelin, GLP-1,
1022	PYY, and GIP Gut Hormones: A Systematic Review and Meta-analysis. Ann Surg
1023	2020;272(1):72-80. doi: 10.1097/sla.000000000003614
1024	10. Crovesy L, Masterson D, Rosado EL. Profile of the gut microbiota of adults with obesity: a
1025	systematic review. Eur J Clin Nutr 2020;74(9):1251-62. doi: 10.1038/s41430-020-0607-6
1026	[published Online First: 20200330]
1027	11. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity
1028	modulate metabolism in mice. Science 2013;341(6150):1241214. doi:
1029	10.1126/science.1241214
1030	12. Hamamah S, Hajnal A, Covasa M. Influence of Bariatric Surgery on Gut Microbiota
1031	Composition and Its Implication on Brain and Peripheral Targets. <i>Nutrients</i> 2024;16(7)
1032	doi: 10.3390/nu16071071 [published Online First: 20240405]
1033	13. Davies NK, O'Sullivan JM, Plank LD, et al. Altered gut microbiome after bariatric surgery
1034	and its association with metabolic benefits: A systematic review. Surg Obes Relat Dis
1035	2019;15(4):656-65. doi: 10.1016/j.soard.2019.01.033 [published Online First: 20190207]
1036	14. Akagbosu CO, Nadler EP, Levy S, et al. The Role of the Gut Microbiome in Pediatric
1037	Obesity and Bariatric Surgery. Int J Mol Sci 2022;23(23) doi: 10.3390/ijms232315421
1038	[published Online First: 20221206]
1039	15. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and
1040	geography. Nature 2012;486(7402):222-7. doi: 10.1038/nature11053 [published Online
1041	First: 2012/06/16]

- 1042 16. Hollister EB, Riehle K, Luna RA, et al. Structure and function of the healthy pre-adolescent
 pediatric gut microbiome. *Microbiome* 2015;3:36. doi: 10.1186/s40168-015-0101-x
 1044 [published Online First: 20150826]
- 1045 17. Agans R, Rigsbee L, Kenche H, et al. Distal gut microbiota of adolescent children is different
 1046 from that of adults. *FEMS Microbiol Ecol* 2011;77(2):404-12. doi: 10.1111/j.15741047 6941.2011.01120.x [published Online First: 20110601]
- 1048 18. Shelton CD, Sing E, Mo J, et al. An early-life microbiota metabolite protects against obesity
 1049 by regulating intestinal lipid metabolism. *Cell Host Microbe* 2023;31(10):1604-19.e10.
 1050 doi: 10.1016/j.chom.2023.09.002 [published Online First: 20231003]
- 1051 19. Vu K, Lou W, Tun HM, et al. From Birth to Overweight and Atopic Disease: Multiple and
 1052 Common Pathways of the Infant Gut Microbiome. *Gastroenterology* 2021;160(1):1281053 44.e10. doi: 10.1053/j.gastro.2020.08.053 [published Online First: 2020/09/19]
- 20. Szczudlik E, Stępniewska A, Bik-Multanowski M, et al. The age of the obesity onset is a
 very important factor for the development of metabolic complications and cardiovascular
 risk in children and adolescents with severe obesity. *Eur J Pediatr* 2024 doi:
 1057 10.1007/s00431-024-05636-x [published Online First: 20240615]
- 1058 21. Draijer L, Voorhoeve M, Troelstra M, et al. A natural history study of paediatric non1059 alcoholic fatty liver disease over 10 years. *JHEP Rep* 2023;5(5):100685. doi:
 1060 10.1016/j.jhepr.2023.100685 [published Online First: 20230125]
- 1061 22. Tommerdahl KL, Kendrick J, Nelson RG, et al. Youth versus adult-onset type 2 diabetic
 1062 kidney disease: Insights into currently known structural differences and the potential
 1063 underlying mechanisms. *Clin Sci (Lond)* 2022;136(21):1471-83. doi:
 1064 10.1042/cs20210627
- Wardman JF, Bains RK, Rahfeld P, et al. Carbohydrate-active enzymes (CAZymes) in the gut
 microbiome. *Nat Rev Microbiol* 2022;20(9):542-56. doi: 10.1038/s41579-022-00712-1
 [published Online First: 20220328]
- 1068 24. Farin W, Oñate FP, Plassais J, et al. Impact of laparoscopic Roux-en-Y gastric bypass and
 1069 sleeve gastrectomy on gut microbiota: a metagenomic comparative analysis. *Surg Obes* 1070 *Relat Dis* 2020;16(7):852-62. doi: 10.1016/j.soard.2020.03.014 [published Online First:
 1071 20200320]
- Paganelli FL, Luyer M, Hazelbag CM, et al. Roux-Y Gastric Bypass and Sleeve Gastrectomy
 directly change gut microbiota composition independent of surgery type. *Sci Rep* 2019;9(1):10979. doi: 10.1038/s41598-019-47332-z [published Online First: 20190729]
- Porat D, Vaynshtein J, Gibori R, et al. Stomach pH before vs. after different bariatric surgery
 procedures: Clinical implications for drug delivery. *Eur J Pharm Biopharm*
- 2021;160:152-57. doi: 10.1016/j.ejpb.2021.01.016 [published Online First: 20210130]
 27. Koutoukidis DA, Jebb SA, Zimmerman M, et al. The association of weight loss with changes in the gut microbiota diversity, composition, and intestinal permeability: a systematic
 review and meta-analysis. *Gut Microbes* 2022;14(1):2020068. doi:
- 1081 10.1080/19490976.2021.2020068
- Sidar A, Voshol GP, Vijgenboom E, et al. Novel Design of an α-Amylase with an N-Terminal
 CBM20 in Aspergillus niger Improves Binding and Processing of a Broad Range of
 Starches. *Molecules* 2023;28(13) doi: 10.3390/molecules28135033 [published Online
 First: 20230627]

- Liao C, Rolling T, Djukovic A, et al. Oral bacteria relative abundance in faeces increases due
 to gut microbiota depletion and is linked with patient outcomes. *Nat Microbiol* 2024 doi:
 1088 10.1038/s41564-024-01680-3 [published Online First: 20240502]
- 30. Read E, Curtis MA, Neves JF. The role of oral bacteria in inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol* 2021;18(10):731-42. doi: 10.1038/s41575-021-00488-4
 [published Online First: 20210816]
- 1092 31. Sayols-Baixeras S, Dekkers KF, Baldanzi G, et al. Streptococcus Species Abundance in the
 1093 Gut Is Linked to Subclinical Coronary Atherosclerosis in 8973 Participants From the
 1094 SCAPIS Cohort. *Circulation* 2023;148(6):459-72. doi:

1095 10.1161/circulationaha.123.063914 [published Online First: 20230712]

- 32. Wahlström A, Sayin SI, Marschall HU, et al. Intestinal Crosstalk between Bile Acids and
 Microbiota and Its Impact on Host Metabolism. *Cell Metab* 2016;24(1):41-50. doi:
 101016/j.cmet.2016.05.005 [published Online First: 20160616]
- 33. Fragkos KC, Forbes A. Citrulline as a marker of intestinal function and absorption in clinical
 settings: A systematic review and meta-analysis. United European Gastroenterol J
 2018;6(2):181-91. doi: 10.1177/2050640617737632 [published Online First: 20171012]
- 34. Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to
 enterocyte mass reduction. *Clin Nutr* 2008;27(3):328-39. doi: 10.1016/j.clnu.2008.02.005
 [published Online First: 20080428]
- 35. Azizi S, Mahdavi R, Mobasseri M, et al. The impact of L-citrulline supplementation on
 glucose homeostasis, lipid profile, and some inflammatory factors in overweight and
 obese patients with type 2 diabetes: A double-blind randomized placebo-controlled trial. *Phytother Res* 2021;35(6):3157-66. doi: 10.1002/ptr.6997 [published Online First:
 20210420]
- 36. Eshreif A, Al Batran R, Jamieson KL, et al. l-Citrulline supplementation improves glucose
 and exercise tolerance in obese male mice. *Exp Physiol* 2020;105(2):270-81. doi:
 10.1113/ep088109 [published Online First: 20200115]
- 37. Holguin F, Grasemann H, Sharma S, et al. L-Citrulline increases nitric oxide and improves
 control in obese asthmatics. *JCI Insight* 2019;4(24) doi: 10.1172/jci.insight.131733
 [published Online First: 20191219]
- 38. Joffin N, Jaubert AM, Durant S, et al. Citrulline induces fatty acid release selectively in visceral adipose tissue from old rats. *Mol Nutr Food Res* 2014;58(9):1765-75. doi: 10.1002/mnfr.201400053 [published Online First: 20140610]
- 39. Strandwitz P. Neurotransmitter modulation by the gut microbiota. *Brain Res* 2018;1693(Pt
 B):128-33. doi: 10.1016/j.brainres.2018.03.015
- 40. Blaner WS. Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic
 disorders. *Pharmacol Ther* 2019;197:153-78. doi: 10.1016/j.pharmthera.2019.01.006
 [published Online First: 20190129]
- 41. Juárez-Fernández M, Román-Sagüillo S, Porras D, et al. Long-Term Effects of Bariatric
 Surgery on Gut Microbiota Composition and Faecal Metabolome Related to Obesity
 Remission. *Nutrients* 2021;13(8) doi: 10.3390/nu13082519 [published Online First:
 20210723]
- 42. Anhê FF, Zlitni S, Zhang SY, et al. Human gut microbiota after bariatric surgery alters
 intestinal morphology and glucose absorption in mice independently of obesity. *Gut*2023;72(3):460-71. doi: 10.1136/gutjnl-2022-328185 [published Online First: 20220825]

1131	43. Yadav J, Liang T, Qin T, et al. Gut microbiome modified by bariatric surgery improves
1132	insulin sensitivity and correlates with increased brown fat activity and energy
1133	expenditure. Cell Rep Med 2023;4(5):101051. doi: 10.1016/j.xcrm.2023.101051
1134	44. Tremaroli V, Karlsson F, Werling M, et al. Roux-en-Y Gastric Bypass and Vertical Banded
1135	Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to
1136	Fat Mass Regulation. Cell Metab 2015;22(2):228-38. doi: 10.1016/j.cmet.2015.07.009
1137	45. Rohm TV. Meier DT. Olefsky JM. et al. Inflammation in obesity, diabetes, and related
1138	disorders. Immunity 2022;55(1):31-55. doi: 10.1016/j.immuni.2021.12.013
1139	46. Bianchi VE. Weight loss is a critical factor to reduce inflammation. <i>Clin Nutr ESPEN</i>
1140	2018:28:21-35. doi: 10.1016/i.clnesp.2018.08.007 [published Online First: 20180903]
1141	47. Fukuda N. Ojima T. Havata K. et al. Laparoscopic sleeve gastrectomy for morbid obesity
1142	improves gut microbiota balance, increases colonic mucosal-associated invariant T cells
1143	and decreases circulating regulatory T cells. Surg Endosc 2022:36(10):7312-24. doi:
1144	10.1007/s00464-022-09122-z [published Online First: 20220219]
1145	48. Pang SS. Le YY. Role of resistin in inflammation and inflammation-related diseases. <i>Cell</i>
1146	Mol Immunol 2006:3(1):29-34.
1147	49. Taouis M. Benomar Y. Is resistin the master link between inflammation and inflammation-
1148	related chronic diseases? <i>Mol Cell Endocrinol</i> 2021:533:111341. doi:
1149	10.1016/i.mce.2021.111341 [published Online First: 20210531]
1150	50. Schnell A, Littman DR, Kuchroo VK, T(H)17 cell heterogeneity and its role in tissue
1151	inflammation. <i>Nat Immunol</i> 2023:24(1):19-29. doi: 10.1038/s41590-022-01387-9
1152	[nublished Online First: 20230103]
1153	51 Chen L Ruan G Cheng Y et al. The role of Th17 cells in inflammatory bowel disease and
1154	the research progress. Front Immunol 2022:13:1055914. doi:
1155	10 3389/fimmu 2022 1055914 [nublished Online First: 20230109]
1156	52. Kaakoush NO. Insights into the Role of Erysipelotrichaceae in the Human Host. Front Cell
1157	Infect Microbiol 2015:5:84. doi: 10.3389/fcimb.2015.00084 [published Online First:
1158	20151120]
1159	53. Miyauchi E, Kim SW, Suda W, et al. Gut microorganisms act together to exacerbate
1160	inflammation in spinal cords. <i>Nature</i> 2020;585(7823):102-06. doi: 10.1038/s41586-020-
1161	2634-9 [published Online First: 20200826]
1162	54. Kawano Y. Edwards M. Huang Y. et al. Microbiota imbalance induced by dietary sugar
1163	disrupts immune-mediated protection from metabolic syndrome. <i>Cell</i>
1164	2022:185(19):3501-19.e20. doi: 10.1016/i.cell.2022.08.005 [published Online First:
1165	20220829]
1166	55. Westerink F. Huibregtse I. De Hoog M. et al. Faecal Inflammatory Biomarkers and
1167	Gastrointestinal Symptoms after Bariatric Surgery: A Longitudinal Study. Inflamm Intest
1168	<i>Dis</i> 2021;6(2):109-16. doi: 10.1159/000514576 [published Online First: 20210414]
1169	56. Serrano E. Bastard JP. Trystram L. et al. Serum Versus Fecal Calprotectin Levels in Patients
1170	with Severe Obesity Before and 6 Months After Roux-Y-Gastric Bypass: Report of the
1171	Prospective Leaky-Gut Study. Obes Surg 2023;33(12):4017-25. doi: 10.1007/s11695-
1172	023-06911-w [published Online First: 20231104]
1173	57. Liu T, Zhang L, Joo D, et al. NF-κB signaling in inflammation. Signal Transduct Target Ther
1174	2017:2:17023 doi: 10.1038/sigtrans.2017.23 [published Online First: 20170714]
1175	58. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. <i>J Intern Med</i>
1176	2008;263(6):591-6. doi: 10.1111/j.1365-2796.2008.01953.x

1177	59. Sokol H. Pigneur B. Watterlot L. et al. Faecalibacterium prausnitzii is an anti-inflammatory
1178	commensal bacterium identified by gut microbiota analysis of Crohn disease patients.
1179	<i>Proc Natl Acad Sci U S A</i> 2008:105(43):16731-6. doi: 10.1073/pnas.0804812105
1180	[published Online First: 20081020]
1181	60. Rahman MM. McFadden G. Modulation of NF- κ B signalling by microbial pathogens. <i>Nat</i>
1182	<i>Rev Microbiol</i> 2011:9(4):291-306. doi: 10.1038/nrmicro2539 [published Online First:
1183	20110308]
1184	61. Giri R. Hoedt EC. Khushi S. et al. Secreted NF-kB suppressive microbial metabolites
1185	modulate gut inflammation. <i>Cell Rep</i> 2022;39(2):110646. doi:
1186	10.1016/i.celrep.2022.110646
1187	62. Jowe JK, Surapaneni PK, Cruz E, et al. Bariatric Surgery and Inflammatory Bowel Disease:
1188	National Trends and Outcomes Associated with Procedural Sleeve Gastrectomy vs
1189	Historical Bariatric Surgery Among US Hospitalized Patients 2009-2020 Obes Surg
1190	2023:33(11):3472-86 doi: 10.1007/s11695-023-06833-7 [published Online First:
1191	2023,00(11).5 172 00. doi: 10.1007/011095 025 000055 7 [published Online Trist.
1192	63 Kiasat A Granström AI. Stenberg E et al. The risk of inflammatory howel disease after
1193	bariatric surgery Surg Obes Relat Dis 2022:18(3):343-50 doi:
1194	10 1016/i soard 2021 12 014 [published Online First: 20211217]
1195	64 Braga Neto MB Gregory M Ramos GP et al De-novo Inflammatory Bowel Disease After
1196	Bariatric Surgery: A Large Case Series I Crohns Colitis 2018:12(4):452-57 doi:
1197	10 1093/ecco-icc/iix177
1198	65 Glassner KL Abraham BP Quigley FMM The microbiome and inflammatory bowel
1199	disease I Allerov Clin Immunol 2020:145(1):16-27 doi: 10.1016/j.jaci.2019.11.003
1200	[nublished Online First: 2020/01/09]
1200	66 Ramamoorthy S Levy S Mohamed M et al An ambient-temperature storage and
1201	stabilization device performs comparably to flash-frozen collection for stool
1202	metabolomics in infants <i>BMC Microbiol</i> 2021:21(1):59 doi: 10.1186/s12866-021-
1203	02104-6 [nublished Online First: 2021/02/24]
1205	67 FastOC: A Quality Control Tool for High Throughput Sequence Data [Online] [program]
1205	0 11 9 version: Babraham Bioinformatics 2010
1200	68 Fwels P Magnusson M Lundin S, et al MultiOC: summarize analysis results for multiple
1208	tools and samples in a single report <i>Bioinformatics</i> 2016:32(19):3047-8 doi:
1209	10.1093/bioinformatics/btw354 [published Online First: 20160616]
1210	69 Angelova A DD, Subramanian P, Ouiñones M, Dolan M, Hurt DE, WGSA2 workflow - a
1211	tutorial protocolsio 2023 doi: doi:10.17504/protocols io.n921dm98x15b/v1
1212	70 Weber N Liou D Dommer I et al Nenhele: a cloud platform for simplified standardized
1213	and reproducible microbiome data analysis <i>Bioinformatics</i> 2018:34(8):1411-13 doi:
1213	10 1093/bioinformatics/btx617
1215	71 Chen S Zhou Y Chen Y et al. fastn: an ultra-fast all-in-one FASTO preprocessor
1216	<i>Bioinformatics</i> 2018:34(17):i884-i90 doi: 10.1093/bioinformatics/btv560
1210	72 Wood DF Lu I I angread B Improved metagenomic analysis with Kraken 2 Genome Riol
1218	2019·20(1)·257 doi: 10.1186/s13059-019-1891-0 [nublished Online First: 20191128]
1210	73 Nurk S Meleshko D Korobevnikov A et al metaSPAdes: a new versatile metagenomic
1220	assembler Genome Res 2017.27(5):824-34 doi: 10.1101/or.213959.116 [mublished
1220	Online First: 20170315]
1221	Omme 1 16. 201/0515]

- 1222 74. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods* 1223 2012;9(4):357-9. doi: 10.1038/nmeth.1923 [published Online First: 20120304]
- 1224 75. Cantalapiedra CP, Hernández-Plaza A, Letunic I, et al. eggNOG-mapper v2: Functional
 1225 Annotation, Orthology Assignments, and Domain Prediction at the Metagenomic Scale.
 1226 Mol Biol Evol 2021;38(12):5825-29. doi: 10.1093/molbev/msab293
- 76. Zhu Q, Fisher SA, Shallcross J, et al. VERSE: a versatile and efficient RNA-Seq read
 counting tool. *bioRxiv* 2016:053306. doi: 10.1101/053306
- 77. Zheng J, Ge Q, Yan Y, et al. dbCAN3: automated carbohydrate-active enzyme and substrate
 annotation. *Nucleic Acids Res* 2023;51(W1):W115-w21. doi: 10.1093/nar/gkad328
- 1231 78. Camargo AP, Roux S, Schulz F, et al. Identification of mobile genetic elements with
 1232 geNomad. *Nat Biotechnol* 2024;42(8):1303-12. doi: 10.1038/s41587-023-01953-y
 1233 [published Online First: 20230921]
- 79. Zhu Q, Fisher S, Shallcross J, et al. VERSE: a versatile and efficient RNA-Seq read counting
 tool: bioRxiv, 2016.
- 80. Nayfach S, Camargo AP, Schulz F, et al. CheckV assesses the quality and completeness of metagenome-assembled viral genomes. *Nat Biotechnol* 2021;39(5):578-85. doi:
 10.1038/s41587-020-00774-7 [published Online First: 20201221]
- 1239 81. Shaffer M, Borton MA, McGivern BB, et al. DRAM for distilling microbial metabolism to
 1240 automate the curation of microbiome function. *Nucleic Acids Res* 2020;48(16):8883-900.
 1241 doi: 10.1093/nar/gkaa621
- 1242 82. Steinegger M, Söding J. MMseqs2 enables sensitive protein sequence searching for the
 1243 analysis of massive data sets. *Nat Biotechnol* 2017;35(11):1026-28. doi:
 10.1038/nbt.3988 [published Online First: 20171016]
- 83. Guo J, Bolduc B, Zayed AA, et al. VirSorter2: a multi-classifier, expert-guided approach to
 detect diverse DNA and RNA viruses. *Microbiome* 2021;9(1):37. doi: 10.1186/s40168020-00990-y [published Online First: 2021/02/02]
- 84. Roux S, Camargo AP, Coutinho FH, et al. iPHoP: An integrated machine learning framework
 to maximize host prediction for metagenome-derived viruses of archaea and bacteria.
 PLoS Biol 2023;21(4):e3002083. doi: 10.1371/journal.pbio.3002083 [published Online
 First: 20230421]
- 85. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and
 graphics of microbiome census data. *PLoS One* 2013;8(4):e61217. doi:
- 10.1371/journal.pone.0061217 [published Online First: 20130422]
 86. Kuznetsova A, Brockhoff, P. B., & Christensen, R. H. B. ImerTest Package: Tests in Linear
 Mixed Effects Models. *Journal of Statistical Software* 2017;82(13):1.26. doi:
- 1256
 Mixed Effects Models. Journal of Statistical Software 2017;82(13):1-26. doi:

 1257
 10.18637/jss.v082.i13
- 1258 87. Oksanen J BF, Kindt R, Legendre P, Minchin P, O'Hara B, Simpson G, Solymos P, Stevens
 1259 H, Wagner H. Vegan: Community Ecology Package. 2022
- 1260 88. Wickham H. ggplot2: Elegant Graphics for Data Analysis.: Wickham, H. ggplot2: Elegant
 1261 Graphics for Data Analysis. 2016.
- 1262 89. Mallick H, Rahnavard A, McIver LJ, et al. Multivariable association discovery in population1263 scale meta-omics studies. *PLoS Comput Biol* 2021;17(11):e1009442. doi:
 10.1371/journal.pcbi.1009442 [published Online First: 20211116]
- 90. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis.
 BMC Bioinformatics 2008;9:559. doi: 10.1186/1471-2105-9-559 [published Online First: 20081229]

- 1268 91. Rahnavard A, Mann B, Giri A, et al. Metabolite, protein, and tissue dysfunction associated
 1269 with COVID-19 disease severity. *Sci Rep* 2022;12(1):12204. doi: 10.1038/s41598-0221270 16396-9 [published Online First: 20220716]
- 1271 92. Zeng M, Cao H. Fast quantification of short chain fatty acids and ketone bodies by liquid
 1272 chromatography-tandem mass spectrometry after facile derivatization coupled with
 1273 liquid-liquid extraction. *J Chromatogr B Analyt Technol Biomed Life Sci* 2018;1083:1371274 45. doi: 10.1016/j.jchromb.2018.02.040 [published Online First: 2018/03/17]
- 93. Jaochico A, Sangaraju D, Shahidi-Latham SK. A rapid derivatization based LC-MS/MS
 method for quantitation of short chain fatty acids in human plasma and urine. *Bioanalysis*2019;11(8):741-53. doi: 10.4155/bio-2018-0241 [published Online First: 2019/04/18]
- 94. McCloskey D, Gangoiti JA, Palsson BO, et al. A pH and solvent optimized reverse-phase
 ion-paring-LC-MS/MS method that leverages multiple scan-types for targeted absolute
 quantification of intracellular metabolites. *Metabolomics* 2015;11(5):1338-50. doi:
 10.1007/s11306-015-0790-y
- 95. Prinville V, Ohlund L, Sleno L. Targeted Analysis of 46 Bile Acids to Study the Effect of
 Acetaminophen in Rat by LC-MS/MS. *Metabolites* 2020;10(1) doi:
 10.3390/metabo10010026 [published Online First: 2020/01/16]
- 96. Sergushichev AA. An algorithm for fast preranked gene set enrichment analysis using
 cumulative statistic calculation. *bioRxiv* 2016:060012. doi: 10.1101/060012
- P7. Cheung F, Fantoni G, Conner M, et al. Web Tool for Navigating and Plotting SomaLogic
 ADAT Files. *J Open Res Softw* 2017;5 doi: 10.5334/jors.166 [published Online First:
 20170908]
- 98. Kozich JJ, Westcott SL, Baxter NT, et al. Development of a dual-index sequencing strategy
 and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina
 sequencing platform. *Appl Environ Microbiol* 2013;79(17):5112-20. doi:
 10.1128/sem.01042.12 Semblished Online First 20120(21)
- 1293 10.1128/aem.01043-13 [published Online First: 20130621]
- 99. Callahan BJ, McMurdie PJ, Rosen MJ, et al. DADA2: High-resolution sample inference
 from Illumina amplicon data. *Nat Methods* 2016;13(7):581-3. doi: 10.1038/nmeth.3869
 [published Online First: 2016/05/24]
- 100. Rohart F, Gautier B, Singh A, et al. mixOmics: An R package for 'omics feature selection
 and multiple data integration. *PLoS Comput Biol* 2017;13(11):e1005752. doi:
- 1299 10.1371/journal.pcbi.1005752 [published Online First: 20171103]
- 1300
- 1301
- 1301
- 1302
- 1303
- 1304
- 1305
- 1306
- 1307

1308 Table 1: Subject demographics, clinical data, and changes with laparoscopic vertical sleeve

1309 gastrectomy (VSG). Significant p-values in bold.

	Pre-VSG	Post-VSG	P-value
	(n=12)	(n=12)	
Demographics			
Age in years, mean (range)	15 (10-18)		
Female Sex	8 (67%)		
Race:			
White or Caucasian	2 (17%)		
Black or African American	9 (75%)		
Other	1 (8%)		
Hispanic or Latino Ethnicity	1 (8%)		
Clinical			
Body mass index (BMI), kg/m ²	48.7	39.9	<0.0001
Weight in kg, mean (range)	144 (94-195)	120 (67–173)	<0.0001
Diabetes or Prediabetes	8 (3 with	0	0.0078
	diabetes, 5		
	with		
	prediabetes)		
Dyslipidemia	4	1	0.25
Hypertension	4	3	1
HbA1c % (range)	5.6 (5.3-5.9)	5.2 (4.9-5.5)	0.0029
Low-density lipoprotein cholesterol mg/dL	100.9 (64-157)	90.4 (66-126)	0.947
(range)			
High-density lipoprotein cholesterol mg/dL	41.3 (29-58)	49 (42-61)	0.0317
(range)			
Triglycerides mg/dL (range)	111.5 (56-195)	81 (39-114)	0.271
Alanine aminotransferase U/L (range)	28.2 (9-59)	15.7 (6-28)	0.0025









Streptococcus HSISS1 (TAX608) Streptococcus salivarius (TAX589) Actinomyces HMT 175 (TAX4191) Actinomyces oris (TAX4153) Streptococcus FDAARGOS 192 (TAX573) Actinomyces viscosus (TAX4152) Actinomyces naeslundii (TAX575) Streptococcus HSISS3 (TAX614) Actinomyces oral taxon 171 (TAX582) Actinomyces oral taxon 169 (TAX4139) Streptococcus HSISS2 (TAX612) Streptococcus HSISM1 (TAX4054) Streptococcus vestibularis (TAX5687) Streptococcus LPB0220 (TAX566) Streptococcus parasanguinis (TAX588) Actinomyces sp (TAX571) Streptococcus equinus (TAX562) Streptococcus lactarius (TAX580) Schaalia odontolytica (TAX581) Streptococcus sanguinis (TAX729) Rothia dentocariosa (TAX4192) Streptococcus gordonii (TAX4194) Actinomyces Chiba101 (TAX4151) Actinomyces oral taxon 414 (TAX570) Streptococcus sp (TAX1977) Limosilactobacillus fermentum (TAX4145) Pauljensenia hongkongensis (TAX4162) Schaalia meyeri (TAX4177) Schaalia sp (TAX4138) Actinomyces slackii (TAX572) Actinomyces howellii (TAX564) Actinomyces ZJ34 (TAX4150) Actinomyces ZJ750 (TAX4200) Corynebacterium matruchotii (TAX4161) Olsenella uli (TAX1392) Sulfitobacter THAF37 (TAX1137) Kytococcus sedentarius (TAX613)

log Abundance 15 10



pat_10 pat_5 pat_5 pat_13 pat_7 pat_7 pat_14 pat_14 pat_14 pat_3

0

Pre-VSG

Post-VSG

0

Pre-VSG

Post-VSG

-





